<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>00004 Mid Day Module (Pharma-4) - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / Mock Test / Mid Day Module
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">50</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 14568,
    "choices": [
      {
        "id": 58233,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levodopa</span></span></span></p>"
      },
      {
        "id": 58234,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Amantadine</span></span></span></p>"
      },
      {
        "id": 58235,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Trihexyphenidyl</span></span></span></p>"
      },
      {
        "id": 58236,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Selegiline</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A patient with Parkinsonism developed this condition after treatment. Which of the following agents could be the causative agent?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture5.jpg\" style=\"height:134px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "unique_key": "Q5797993",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457814,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Amantadine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The <strong>image</strong> provided appears to show a patient with <strong>marked purplish discoloration and swelling in the lower extremities, </strong>which could be consistent with<strong> livedo reticularis,</strong> a condition known to be a<strong> potential side effect</strong> of some medications like <strong>amantadine.</strong> </span><strong><span style=\"font-size:12.0pt\">Amantadine</span></strong><span style=\"font-size:12.0pt\"> is an <strong>antiviral medication</strong> that is also used in the <strong>treatment of Parkinson&#39;s disease.</strong> One of the<strong> known side effects </strong>of amantadine is <strong>livedo reticularis,</strong> a<strong> mottled discoloration of the skin</strong> that is often <strong>purplish and reticular (net-like)</strong>. This <strong>side effect</strong> can be<strong> reversible</strong> upon<strong> discontinuation of the drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Levodopa</span></strong><span style=\"font-size:12.0pt\">: While levodopa is the<strong> most effective</strong> medication for the management of<strong> Parkinson&#39;s disease symptoms,</strong> it is <strong>not </strong>commonly associated with <strong>skin changes</strong> like those <strong>depicted in the image.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Trihexyphenidyl</span></strong><span style=\"font-size:12.0pt\">: An<strong> anticholinergic drug</strong> used to<strong> treat Parkinsonism, </strong>but it is <strong>not </strong>typically <strong>linked with the skin condition</strong> <strong>shown.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. &nbsp;Selegiline</span></strong><span style=\"font-size:12.0pt\">: An <strong>MAO-B inhibitor </strong>used to help control the <strong>symptoms of Parkinson&#39;s disease</strong>. It also <strong>does not</strong> commonly cause the <strong>skin changes seen in the image</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to recognize the <strong>side effects</strong> associated with <strong>medications </strong>used in the <strong>treatment of Parkinson&#39;s disease</strong>. <strong>Amantadine </strong>can <strong>cause livedo reticularis</strong>, which is characterized by a<strong> purplish, mottled skin discoloration.</strong></span></span></span></p>",
    "correct_choice_id": 58234,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14573,
    "choices": [
      {
        "id": 58253,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine</span></span></span></p>"
      },
      {
        "id": 58254,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenytoin</span></span></span></p>"
      },
      {
        "id": 58255,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenobarbitone</span></span></span></p>"
      },
      {
        "id": 58256,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which antiepileptic drug can cause this adverse effect?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture7.jpg\" style=\"height:227px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q1093531",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457815,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Phenytoin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Figure shows gum hypertrophy caused by Phenytoin. </span><span style=\"font-size:12.0pt\">Phenytoin is an antiepileptic drug known to cause gingival hyperplasia as a side effect. This adverse effect is more commonly associated with phenytoin than with the other antiepileptic drugs listed. The exact mechanism is not fully understood, but it is thought to involve the stimulation of fibroblasts to produce more collagen and other extracellular matrix substances, leading to the overgrowth of gum tissue.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Carbamazepine</span></strong><span style=\"font-size:12.0pt\">: While carbamazepine can have several side effects, it is not typically associated with gingival hyperplasia.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Phenobarbitone</span></strong><span style=\"font-size:12.0pt\">: Phenobarbitone (phenobarbital), another antiepileptic drug, also does not commonly cause gingival hyperplasia.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Valproate</span></strong><span style=\"font-size:12.0pt\">: Valproate does not typically cause gingival hyperplasia as a side effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to recognize the side effects associated with antiepileptic drugs, particularly phenytoin, which is known to cause gingival hyperplasia. Healthcare providers should monitor patients on phenytoin for this condition and educate them about maintaining good oral hygiene to help prevent or minimize this adverse effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs causing gum hypertrophy are:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenytoin</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cyclosporine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Calcium channel blockers like verapamil, diltiazem and nifedipine</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58254,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14586,
    "choices": [
      {
        "id": 58305,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Parkinsonism</span></span></span></p>"
      },
      {
        "id": 58306,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acute muscle dystonia</span></span></span></p>"
      },
      {
        "id": 58307,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tardive dyskinesia</span></span></span></p>"
      },
      {
        "id": 58308,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Akathisia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Propranolol is useful in the management of which of the following side effects of a typical neuroleptic?</span></span></span></p>",
    "unique_key": "Q5652478",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457816,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Akathisia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Propranolol, </strong>a<strong> non-selective beta-blocker,</strong> is useful in the management of<strong> akathisia,</strong> which is a<strong> common side effect</strong> of <strong>typical neuroleptics (antipsychotic drugs).</strong> Akathisia is characterized by a <strong>subjective feeling of restlessness</strong> and an<strong> objective need to move</strong>, often<strong> resulting in</strong> <strong>pacing and inability to sit still</strong>. <strong>Propranolol </strong>helps <strong>alleviate </strong>these symptoms by <strong>blocking beta-adrenergic receptors</strong>, which can<strong> modulate </strong>some of the pathways involved in <strong>akathisia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Parkinsonism:</span></strong><span style=\"font-size:12.0pt\"> Parkinsonism induced by<strong> neuroleptics </strong>is <strong>treated</strong> with <strong>anticholinergic medications</strong>, not beta-blockers like propranolol.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute muscle dystonia:</span></strong><span style=\"font-size:12.0pt\"> Acute dystonia resulting from <strong>neuroleptic use</strong> is usually <strong>treated </strong>with<strong> anticholinergic agents</strong> <strong>or benzodiazepines</strong>, not beta-blockers.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tardive dyskinesia:</span></strong><span style=\"font-size:12.0pt\"> Tardive dyskinesia is a<strong> late-onset movement disorder </strong>caused by<strong> long-term use of neuroleptics</strong>. Treatment options may include <strong>reducing the dose</strong> of the <strong>neuroleptic,</strong> <strong>switching</strong> to a <strong>less potent agent,</strong> or using medications like <strong>valbenazine or</strong> <strong>deutetrabenazine, </strong>not typically beta-blockers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to recognize that <strong>propranolol,</strong> a<strong> beta-blocker,</strong> is <strong>effective</strong> in <strong>managing akathisia,</strong> a <strong>side effect</strong> characterized by<strong> restlessness and an uncontrollable</strong> need to<strong> move</strong>, often associated with the<strong> use of typical neuroleptics. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of extrapyramidal symptoms:</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-172358.jpg\" style=\"height:386px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 58308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14596,
    "choices": [
      {
        "id": 58345,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine </span></span></span></p>"
      },
      {
        "id": 58346,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Topiramate </span></span></span></p>"
      },
      {
        "id": 58347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ACTH </span></span></span></p>"
      },
      {
        "id": 58348,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Vigabatrin </span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 6-month-old infant presents with a history of infantile spasms and has recently been diagnosed with a visual field defect. The pediatric neurologist discusses treatment options with the parents, emphasizing the need for effective management of the spasms while also considering the potential side effects of medications. Which of the following drugs, despite being highly effective for treating infantile spasms, is not used in this patient due to the risk of exacerbating the visual defect?</span></span></p>",
    "unique_key": "Q1725512",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457817,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Vigabatrin </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vigabatrin</strong> is a<strong> medication</strong> that is<strong> highly effective </strong>in the <strong>treatment of infantile spasms,</strong> particularly those associated with<strong> tuberous</strong> <strong>sclerosis.</strong> However, its use is associated with a<strong> risk of permanent visual field defects, </strong>making it <strong>contraindicated </strong>or used <strong>with caution</strong> in <strong>patients with pre-existing</strong> <strong>visual problems </strong>or when the<strong> risk of such adverse effects</strong> <strong>outweighs</strong> the<strong> benefits.</strong> In a child with <strong>infantile spasms</strong> and a <strong>visual defect</strong>,<strong> vigabatrin</strong> <strong>would not</strong> be the preferred <strong>choice </strong>due to this <strong>risk.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> Lamotrigine is an <strong>antiepileptic drug </strong>used for <strong>various seizure types</strong> but is <strong>not</strong> the <strong>first-line treatment</strong> for <strong>infantile spasms. </strong>It <strong>does not</strong> have a<strong> high risk </strong>of<strong> causing</strong> or <strong>exacerbating visual field defects.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Topiramate:</span></strong><span style=\"font-size:12.0pt\"> Topiramate is another <strong>antiepileptic</strong> that <strong>can be used </strong>in the management of<strong> infantile spasms</strong> but is also<strong> not</strong> primarily associated with<strong> visual field </strong>defects as a common adverse effect.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ACTH (Adrenocorticotropic hormone):</span></strong><span style=\"font-size:12.0pt\"> ACTH is a<strong> standard treatment</strong> for <strong>infantile spasms </strong>and <strong>does not</strong> directly cause <strong>visual field defects</strong>, making it a suitable option for this condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to<strong> identify vigabatrin</strong> as an <strong>effective treatment</strong> for<strong> infantile spasms</strong> that is <strong>contraindicated in patients</strong> with <strong>pre-existing visual field defects</strong> due to the<strong> risk of exacerbating or causing permanent visual damage.</strong></span></span></span></p>",
    "correct_choice_id": 58348,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14602,
    "choices": [
      {
        "id": 58369,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Chlordiazepoxide</span></span></span></p>"
      },
      {
        "id": 58370,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Diazepam</span></span></span></p>"
      },
      {
        "id": 58371,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Lorazepam</span></span></span></p>"
      },
      {
        "id": 58372,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Flunitrazepam</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of chronic liver disease is admitted to the hospital for alcohol withdrawal management. Given his liver condition, the healthcare team needs to choose a medication that is safe and effective for managing his withdrawal symptoms while considering the potential impact on his liver function. Which of the following agents is most appropriate for managing alcohol withdrawal in this patient with liver disease?</span></span></p>",
    "unique_key": "Q1624936",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457818,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Lorazepam </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Benzodiazepines (BZDs) </strong>are the <strong>drugs of choice</strong> to treat <strong>alcohol withdrawal.</strong> <strong>Chlordiazepoxide</strong> is the <strong>first choice. Diazepam</strong> is the <strong>alternative.</strong><strong> </strong>But <strong>all BZDs </strong>given in the options (<strong>Chlordiazepoxide Diazepam and flunitrazepam</strong>) are <strong>metabolized extensively</strong> by <strong>enzyme CYP3A4 In liver and active metabolites </strong>are generated. Oxazepam, Lorazepam Temazepam are <strong>not metabolized</strong> but directly <strong>conjugated </strong>therefore they are<strong> relatively safer </strong>in <strong>elderly patients </strong>and in those with<strong> liver disease.</strong> <strong>&nbsp;</strong></span><span style=\"font-size:12.0pt\">Thus, <strong>Lorazepam (option C)</strong> is a <strong>benzodiazepine</strong> that is preferred for managing <strong>alcohol withdrawal symptoms</strong> in patients with <strong>liver disease</strong>. It <strong>undergoes</strong> <strong>glucuronidation </strong>rather than oxidation. This makes<strong> lorazepam a safer option</strong> for patients with<strong> compromised liver function</strong>, as it is <strong>less likely</strong> to <strong>accumulate to toxic levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chlordiazepoxide:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While chlordiazepoxide is<strong> commonly used </strong>for <strong>alcohol withdrawal,</strong> its<strong> metabolism</strong> is significantly affected by <strong>liver function,</strong> making it a<strong> less ideal choice</strong> for patients with <strong>liver disease</strong> due to the <strong>risk of accumulation and increased side effects</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Diazepam:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Diazepam is<strong> metabolized by the liver,</strong> and <strong>its active metabolites </strong>can <strong>accumulate in patients with liver disease,</strong> potentially leading to <strong>prolonged sedation and increased toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Flunitrazepam:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Flunitrazepam is also <strong>metabolized by the liver,</strong> and like <strong>diazepam,</strong> it can <strong>accumulate in patients </strong>with <strong>liver</strong> <strong>impairment,</strong> making it a <strong>less favorable option.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to understand that <strong>lorazepam</strong> is the preferred<strong> benzodiazepine</strong> for managing <strong>alcohol withdrawal symptoms in patients with liver disease </strong>due to its <strong>metabolism through glucuronidation,</strong> which is <strong>less</strong> affected by <strong>liver function</strong> compared to the<strong> oxidative metabolism</strong> of<strong> other benzodiazepines. </strong></span></span></span></p>",
    "correct_choice_id": 58371,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14617,
    "choices": [
      {
        "id": 58429,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Side effects of hydrochlorothiazide</span></span></span></p>"
      },
      {
        "id": 58430,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Decreased metabolism of hydrochlorothiazide by lithium.</span></span></span></p>"
      },
      {
        "id": 58431,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increased renal tubular reabsorption of lithium.</span></span></span></p>"
      },
      {
        "id": 58432,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thiazide acts as an add on drug to lithium.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with bipolar disorder was treated with lithium. Hydrochlorothiazide was prescribed for his hypertension. He developed nausea, vomiting, coarse tremors and brisk reflexes 2 weeks after taking drugs. What is the likely reason for this presentation? </span></span></p>",
    "unique_key": "Q1324794",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457819,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Increased renal tubular reabsorption of lithium.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>most likely cause </strong>of the patient&#39;s symptoms, including<strong> nausea, vomiting, coarse tremors,</strong> and <strong>brisk reflexes,</strong> is <strong>increased renal tubular reabsorption</strong> of <strong>lithium.</strong> When <strong>hydrochlorothiazide, a thiazide diuretic, </strong>is <strong>administered</strong> <strong>alongside lithium,</strong> it can<strong> lead to</strong> <strong>decreased renal clearance of lithium</strong> by <strong>increasing its reabsorption in the renal tubules</strong>. This pharmacological interaction results in <strong>elevated serum lithium levels</strong>, potentially <strong>culminating</strong> in <strong>lithium toxicity.</strong> The <strong>symptoms of lithium toxicity </strong>closely align with <strong>those experienced by</strong> the<strong> patient,</strong> making this<strong> option</strong> the <strong>most plausible explanation</strong> for the clinical presentation observed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Calibri, sans-serif\"><span style=\"font-size:16px\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Side effects of hydrochlorothiazide:</span></strong><span style=\"font-size:12.0pt\"> While <strong>hydrochlorothiazide </strong>can cause side effects like <strong>electrolyte imbalances and dehydration</strong>, its <strong>common side effects do not</strong> typically include the combination of symptoms seen in<strong> lithium toxicity</strong> (<strong>nausea, vomiting, coarse</strong> <strong>tremors, and brisk reflexes</strong>). These<strong> symptoms </strong>are <strong>more specifically</strong> indicative of <strong>lithium</strong> <strong>toxicity</strong> <strong>rather than</strong> direct <strong>side effects of hydrochlorothiazide.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreased metabolism of hydrochlorothiazide by lithium:</span></strong><span style=\"font-size:12.0pt\"> Lithium <strong>does not</strong> significantly impact the<strong> metabolism of hydrochlorothiazide.</strong> The<strong> metabolism and clearance</strong> of <strong>hydrochlorothiazide </strong>are primarily<strong> renal</strong> and are <strong>not</strong> substantially <strong>altered by concurrent</strong> <strong>lithium use,</strong> making this option an <strong>unlikely cause </strong>of the<strong> patient&#39;s symptoms.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Thiazide acts as an add-on drug to lithium:</span></strong><span style=\"font-size:12.0pt\"> There is <strong>no</strong> evidence to suggest that thiazide diuretics <strong>act as add-on drugs to enhance the therapeutic effects of lithium</strong> in the treatment of <strong>bipolar disorder</strong>. The <strong>interaction between hydrochlorothiazide and lithium</strong> that is of clinical significance relates to the <strong>effect on lithium&#39;s renal handling</strong>, <strong>rather </strong>than a <strong>synergistic effect </strong>on <strong>mood stabilization.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The key learning point from this scenario is understanding the<strong> pharmacological interaction</strong> <strong>between lithium and thiazide diuretics</strong>, such as <strong>hydrochlorothiazide</strong>, and how this <strong>interaction</strong> can lead to <strong>increased serum lithium levels </strong>and <strong>subsequent lithium toxicity. </strong></span></span></p>",
    "correct_choice_id": 58431,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14620,
    "choices": [
      {
        "id": 58441,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Migraine</span></span></p>"
      },
      {
        "id": 58442,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lennox Gastaut syndrome</span></span></p>"
      },
      {
        "id": 58443,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Attention Deficit Hyperactivity Disorder</span></span></p>"
      },
      {
        "id": 58444,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dementia</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topiramate is used in the treatment of?</span></span></span></p>",
    "unique_key": "Q7232425",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457820,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Lennox Gastaut syndrome.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Topiramate</strong> is a medication with<strong> multiple indications.</strong> Let&#39;s evaluate each of the options provided:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;Lennox-Gastaut syndrome</strong>: This is a<strong> correct indication </strong>for <strong>topiramate.</strong> It is one of the <strong>medications</strong> that can be<strong> used to</strong> manage <strong>seizures associated with Lennox-Gastaut syndrome,</strong> which is a <strong>severe form of childhood-onset epilepsy</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Migraine</strong>:<strong> Topiramate</strong> is used as a<strong> prophylactic agent for migraine</strong>. It&#39;s <strong>not </strong>used to treat an <strong>acute attack of migraine </strong>but rather to <strong>decrease the frequency, severity, and duration of migraine headaches </strong>when<strong> taken regularly.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Attention Deficit Hyperactivity Disorder (ADHD</strong>): <strong>Topiramate</strong> is <strong>not </strong>a <strong>standard</strong> treatment for <strong>ADHD</strong>. The primary treatments for<strong> ADHD are stimulant medications</strong>, such as <strong>methylphenidate and amphetamines,</strong> as well as certain <strong>non-stimulant medications.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Dementia</strong>: <strong>Topiramate</strong> is <strong>not</strong> indicated for the treatment of <strong>dementia</strong>. <strong>Treatments</strong> for<strong> dementia</strong> typically include<strong> cholinesterase inhibitors and memantine</strong>, which are aimed at <strong>improving cognitive symptoms</strong> or <strong>slowing their progression.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NON-ANTIEPILEPTIC USES OF TOPIRAMATE:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-182151.jpg\" style=\"height:590px; width:1000px\" /></span></span></u></strong></p>",
    "correct_choice_id": 58442,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14601,
    "choices": [
      {
        "id": 58365,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tachycardia</span></span></span></p>"
      },
      {
        "id": 58366,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Respiratory depression</span></span></span></p>"
      },
      {
        "id": 58367,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Urinary retention</span></span></span></p>"
      },
      {
        "id": 58368,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Severe itching</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is operated on for bile duct stricture. Post operatively he is receiving 3 ml epidural morphine for pain relief. One day he accidentally received 12 ml of morphine. What will not occur? </span></span></p>",
    "unique_key": "Q3760613",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457821,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Tachycardia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Epidural administration of morphine</strong> can provide <strong>excellent pain relief, </strong>but it <strong>can</strong> also <strong>lead to adverse effects</strong> such as <strong>respiratory depression, urinary retention, and pruritus </strong>(<strong>severe itching</strong>). The <strong>risk </strong>of <strong>adverse effects is higher</strong> if the patient receives an <strong>overdose of morphine</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Tachycardia </strong>is <strong>not</strong> a<strong> common adverse effect of morphine</strong>, and it is<strong> not </strong>expected to occur in response to an <strong>overdose.</strong> Rather<strong> bradycardia </strong>can be seen<strong> due to depression of cardiovascular centre in brain.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vomiting and retching</strong> are <strong>common adverse effects of morphine</strong> and can <strong>occur</strong> with an <strong>overdose. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Respiratory depression</strong> is the most significant <strong>adverse effect of morphine </strong>and can be <strong>life-threatening in severe cases. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Urinary retention </strong>is another common <strong>adverse effect</strong> of morphine that occurs due to the <strong>inhibition of bladder</strong> <strong>contractions. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Severe itching, or pruritus,</strong> is another common <strong>adverse effect of morphine</strong> that can be<strong> bothersome</strong> for the patient.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58365,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14484,
    "choices": [
      {
        "id": 57897,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Polycystic ovarian syndrome </span></span></span></p>"
      },
      {
        "id": 57898,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Alopecia</span></span></span></p>"
      },
      {
        "id": 57899,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Weight loss </span></span></span></p>"
      },
      {
        "id": 57900,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tremor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which one of the following is a gender specific side effect of valproate? </span></span></span></p>",
    "unique_key": "Q2247699",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457822,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Polycystic ovarian syndrome</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Valproate</strong>, an <strong>antiepileptic drug</strong> used to<strong> treat seizures and mood disorders</strong>, has been associated with the <strong>development of polycystic</strong> <strong>ovarian syndrome (PCOS) in women</strong>. PCOS is characterized by the<strong> presence of ovarian cysts, irregular menstrual cycles,</strong> and <strong>elevated androgen levels,</strong> which can<strong> lead to</strong> symptoms such as<strong> hirsutism and acne.</strong> The <strong>link between</strong> <strong>valproate and PCOS </strong>is particularly noted in <strong>young women</strong> who use the<strong> drug over long periods, </strong>making it a significant<strong> gender-specific side effect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alopecia:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While <strong>hair loss</strong> is a known side effect of <strong>valproate</strong>, it is not gender-specific.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Weight loss:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Weight gain</strong>, rather than loss, is <strong>more </strong>commonly associated <strong>with valproate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tremor:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This <strong>side effec</strong>t is not gender-specific and can affect <strong>anyone taking valproate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The use of <strong>valproate in young women </strong>needs <strong>careful </strong>consideration <strong>due to the risk of inducing polycystic ovarian syndrome, </strong>a <strong>serious and gender-specific side effect</strong>, underscoring the need for <strong>monitoring </strong>and possibly<strong> seeking alternative treatments</strong> where <strong>feasible.</strong></span></span></p>",
    "correct_choice_id": 57897,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14493,
    "choices": [
      {
        "id": 57933,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Venlafaxine</span></span></span></p>"
      },
      {
        "id": 57934,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fluoxetine</span></span></span></p>"
      },
      {
        "id": 57935,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      },
      {
        "id": 57936,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Olanzapine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Stoppage of which of the following drugs can result in anxiety and insomnia causing discontinuation syndrome? </span></span></span></p>",
    "unique_key": "Q1604156",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457823,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\">Ans. A) Venlafaxine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><strong>Discontinuation syndrome</strong> refers to a<strong> set of symptoms</strong> that can occur after <strong>abruptly stopping or significantly reducing</strong> the <strong>dose of certain medications</strong>, particularly those that affect <strong>neurotransmitter levels </strong>in the brain such as <strong>antidepressants. </strong>&nbsp;Common <strong>symptoms of discontinuation syndrome </strong>include<strong> anxiety, insomnia, dizziness, irritability,</strong> <strong>flu-like symptoms, and sensory disturbances </strong>(e.g., &quot;<strong>electric shock&quot;</strong> sensations). The <strong>severity and</strong> <strong>duration</strong> of symptoms can vary depending on th<strong>e drug&#39;s half-life, dosage, and the duration of treatment</strong>. <strong>Discontinuation syndrome</strong> is commonly noted with all <strong>antidepressants</strong> including <strong>SSRI, SNRI and MAO inhibitors.</strong> It is <strong>less</strong> frequently noted with <strong>fluxoetine</strong> because of<strong> its long half life</strong>. <strong>Gradual tapering</strong> of the medication <strong>under medical</strong> <strong>supervision is recommended</strong> to<strong> minimize the risk</strong> of <strong>discontinuation syndrome.</strong></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:&nbsp;Venlafaxine:</strong>&nbsp;It is an <strong>SNRI (serotonin-norepinephrine reuptake inhibitor),</strong> is known for its <strong>potent effects </strong>on <strong>both serotonin</strong> and <strong>norepinephrine reuptake</strong>. <strong>Discontinuation </strong>of<strong> venlafaxine</strong>, especially <strong>abruptly,</strong> can lead to a <strong>significant and distressing</strong> <strong>withdrawal</strong> syndrome characterized by<strong> anxiety, insomnia, and other physical and psychological symptoms. </strong>This is <strong>due to the rapid</strong> <strong>decline in neurotransmitter levels </strong>that had been maintained by the medication.</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Fluoxetine:</strong> <strong>Less </strong>likely to cause <strong>severe discontinuation syndrome</strong> due to <strong>its long half-life, </strong>which provides a <strong>natural</strong> <strong>tapering effect.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Valproate:</strong> An <strong>antiepileptic drug</strong> that<strong> does not</strong> typically cause <strong>discontinuation syndrome </strong>related to<strong> mood alterations</strong> like <strong>anxiety and insomnia.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Olanzapine:</strong> While<strong> stopping antipsychotics</strong> like<strong> olanzapine </strong>can lead to <strong>withdrawal symptoms</strong>, they <strong>do not</strong> typically manifest as <strong>anxiety and insomnia</strong> linked to <strong>discontinuation syndrome.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Venlafaxine</strong> <strong>discontinuation</strong> needs to be <strong>managed</strong> <strong>carefully to avoid severe withdrawal symptoms</strong>, often requiring a <strong>gradual</strong> <strong>tapering of the dose</strong> under medical supervision to <strong>mitigate the risk</strong> of<strong> discontinuation syndrome.</strong></span></span></p>",
    "correct_choice_id": 57933,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14575,
    "choices": [
      {
        "id": 58261,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acute dystonia</span></span></span></p>"
      },
      {
        "id": 58262,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Seizures</span></span></span></p>"
      },
      {
        "id": 58263,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Malingering</span></span></span></p>"
      },
      {
        "id": 58264,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Akathisia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A young male patient who is a case of schizophrenia was started on haloperidol 5 mg. On the 3rd day, he came to the hospital accompanied by his father with rolling up both eyes. A complete neurological examination revealed no spasticity or any other abnormalities. Visual acuity was found to be normal. Most likely diagnosis is: </span></span></span></p>",
    "unique_key": "Q2210321",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457824,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Acute dystonia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis in this scenario is acute dystonia, which is a type of extrapyramidal symptom (EPS) that can occur as a side effect of antipsychotic medications such as haloperidol.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute dystonia typically presents as involuntary muscle contractions, often involving the muscles of the neck, tongue, or eyes. In this case, the patient&#39;s rolling up of both eyes suggests involvement of the muscles controlling eye movements. Acute dystonia usually occurs within the first few days of treatment with an antipsychotic medication and can be a medical emergency if left untreated.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Seizures:</span></strong><span style=\"font-size:12.0pt\"> are unlikely to present with rolling up of both eyes without any other accompanying symptoms such as convulsions or loss of consciousness.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Malingering:</span></strong><span style=\"font-size:12.0pt\"> &nbsp;or feigning symptoms for secondary gain, is also unlikely in this case as there is no obvious reason for the patient to fake these symptoms.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Akathisia: </span></strong><span style=\"font-size:12.0pt\">&nbsp;another type of EPS, presents as restlessness, agitation, and inability to sit still, and is unlikely to cause the rolling up of both eyes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anticholinergic drugs like benzhexol is drug of choice for treatment of acute muscular dystonia. Alternative drugs are first generation histamine H1 blockers like promethazine. </span></span></li>\r\n</ul>",
    "correct_choice_id": 58261,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14588,
    "choices": [
      {
        "id": 58313,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">More potently blocks 5HT2 as compared to D2 receptors.</span></span></span></p>"
      },
      {
        "id": 58314,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Blood level below 350 ng/ml should be maintained to avoid agranulocytosis.</span></span></span></p>"
      },
      {
        "id": 58315,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Should not be used along with Carbamazepine.</span></span></span></p>"
      },
      {
        "id": 58316,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Should be discontinued if the WBC count is below 3,000/mm3 cells.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All are true about Clozapine except</span></span></span></p>",
    "unique_key": "Q9127716",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457825,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Blood level below 350 ng/ml should be maintained to avoid agranulocytosis.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The<strong> false</strong> statement about <strong>clozapine is option B, </strong>which states that <strong>&quot;Blood level below 350</strong> <strong>ng/ml </strong>should be maintained to <strong>avoid agranulocytosis.</strong>&quot; This statement is<strong> not true </strong>because there is <strong>no specific blood level of clozapine</strong> that is associated with the<strong> risk of agranulocytosis</strong>, which is<strong> dose-independent adverse effect of clozapine</strong>.<strong> High plasma</strong> <strong>concentration of Clozapine</strong> increases the<strong> risk of seizures (dose-dependent)</strong>. However, the usual <strong>plasma concentration </strong>required in many people is <strong>300-600 ng/ml.</strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Clozapine</strong> is an <strong>atypical antipsychotic</strong> drug that has <strong>high potency to block 5HT2</strong> <strong>receptors</strong> as <strong>compared to D2 receptors.</strong> However, it also<strong> blocks D4 receptors,</strong> <strong>muscarinic receptors, alpha receptors </strong>and <strong>H1 receptors. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It<strong> suppresses both positive</strong> as well as<strong> negative symptoms of schizophrenia</strong>. It is the<strong> first FDA</strong> approved drug for <strong>anti-suicide indication.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is used only as a<strong> reserve drug</strong> due to the<strong> risk of precipitation of seizures </strong>(<strong>even</strong> in<strong> non-epileptics</strong>) and<strong> agranulocytosis.</strong> <strong>Convulsions</strong> are <strong>dose-dependent </strong>adverse effects seen only<strong> at higher doses </strong>whereas <strong>agranulocytosis is independent</strong> of <strong>dose.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Clozapine</strong> should be <strong>started at low doses (12.5 mg) </strong>and <strong>gradually dose </strong>should be <strong>increased.</strong> <strong>Baseline WBC counts</strong> should be <strong>measured, </strong>and then <strong>weekly counts</strong> should be done<strong> at least for the first 6 months</strong>. When <strong>WBC count </strong>becomes <strong>less</strong> <strong>than 3000/mm3</strong> or <strong>absolute neutrophil </strong>count becomes<strong> less than 1500/mm3,</strong> <strong>Clozapine</strong> should be<strong> discontinued.</strong> <strong>After discontinuation,</strong> <strong>weekly WBC counts</strong> should be measured for an<strong> additional 4 weeks.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It should<strong> not</strong> be used with<strong> Carbamazepine</strong> due to two reasons:</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Carbamazepine</strong> <strong>induces its metabolism </strong>and thus <strong>decreases plasma concentration.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Carbamazepine </strong>has<strong> bone marrow suppressant action </strong>and can add to <strong>agranulocytosis </strong>caused by <strong>Clozapine</strong>.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
    "correct_choice_id": 58314,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14452,
    "choices": [
      {
        "id": 57769,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levodopa is an active metabolite of dopamine.</span></span></span></p>"
      },
      {
        "id": 57770,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">About 50% of administered levodopa is peripherally converted to carbidopa.</span></span></span></p>"
      },
      {
        "id": 57771,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">About 2 % of the administered levodopa crosses blood brain barrier.&nbsp;&nbsp;</span></span></span></p>"
      },
      {
        "id": 57772,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levodopa is a first line drug in the treatment of hepatic coma.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">True about anti - Parkinson drug levodopa is?</span></span></span></p>",
    "unique_key": "Q3056515",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457826,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) About 2% of the administered levodopa crosses the blood brain border.&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Levodopa</strong> is <strong>effectively used</strong> in the treatment of <strong>Parkinson&rsquo;s disease,</strong> primarily because it serves as a <strong>precursor to dopamine,</strong> a <strong>neurotransmitter</strong> that is <strong>deficient in patients with Parkinson&#39;s. Once administered, levodopa </strong>is<strong> converted</strong> into <strong>dopamine</strong> within the <strong>brain to alleviate symptoms </strong>such as <strong>tremors, rigidity, and bradykinesia</strong>. However, the challenge with<strong> levodopa</strong> treatment is its limited ability to<strong> cross the blood-brain barrier</strong>&mdash;only about <strong>1-3% of administered levodopa </strong>reaches the brain. To improve this <strong>delivery and increase the amount of levodopa</strong> reaching the<strong> brain,</strong> it is often <strong>administered with carbidopa,</strong> an <strong>inhibitor </strong>of the enzyme (aromatic <strong>L-amino acid decarboxylase</strong>) that <strong>converts levodopa to dopamine</strong> <strong>outside the brain.</strong> This<strong> inhibition prevents</strong> the <strong>peripheral metabolism of levodopa, </strong>thereby <strong>allowing more</strong> of it to <strong>cross into the brain </strong>where <strong>it can be effective.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Levodopa is an active metabolite of dopamine:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect,</strong> as <strong>levodopa is not a metabolite</strong> <strong>but a precursor </strong>that is <strong>converted to dopamine in the brain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. About 50% of administered levodopa is peripherally converted to carbidopa:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect,</strong> carbidopa is <strong>not</strong> a product of <strong>levodopa metabolism</strong> but is <strong>rather</strong> used to<strong> inhibit the peripheral conversion of levodopa to dopamine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Levodopa is a first-line drug in the treatment of hepatic coma:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect, </strong>as levodopa <strong>is not</strong> used for <strong>hepatic coma</strong>, which is related to<strong> liver failure </strong>and<strong> not </strong>typically managed<strong> </strong>with<strong> dopamine precursors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only a <strong>small fraction (about 1-3%) </strong>of administered <strong>levodopa crosses the blood-brain barrier</strong> to become <strong>active in the brain,</strong> necessitating the<strong> co-administration of carbidopa</strong> to<strong> inhibit its peripheral metabolism</strong> and <strong>increase its central availability</strong> and <strong>effectiveness</strong> in<strong> treating Parkinson&#39;s disease.</strong></span></span></p>",
    "correct_choice_id": 57771,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14473,
    "choices": [
      {
        "id": 57853,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Retigabine</span></span></span></p>"
      },
      {
        "id": 57854,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine</span></span></span></p>"
      },
      {
        "id": 57855,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levetiracetam</span></span></span></p>"
      },
      {
        "id": 57856,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Topiramate</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drug E in the image shown is likely to be?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture4.jpg\" style=\"height:185px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q5498655",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457827,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Retigabine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Retigabine</strong>, also known as<strong> ezogabine,</strong> is an <strong>antiepileptic drug</strong> primarily used as an<strong> adjunctive treatment for focal seizures.</strong> It is unique among <strong>antiepileptic drugs</strong> because<strong> it functions as a neuronal potassium channel opener</strong>. This <strong>mechanism of action helps</strong> <strong>stabilize neuronal membranes</strong> and <strong>reduces excitability, </strong>which <strong>can prevent</strong> the <strong>occurrence of seizures.</strong> <strong>Retigabine</strong> is <strong>distinct </strong>in its <strong>class </strong>due to this<strong> unusual method </strong>of<strong> influencing neuronal activity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> Works by<strong> blocking voltage-gated sodium channels</strong> and <strong>diminishing glutamate</strong> release but <strong>does not </strong>act as a <strong>potassium channel opener.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Levetiracetam:</span></strong><span style=\"font-size:12.0pt\"> Has a unique mechanism involving the <strong>modulation of neurotransmitter release</strong> through <strong>binding to the</strong> <strong>synaptic vesicle protein SV2A.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Topiramate:</span></strong><span style=\"font-size:12.0pt\"> Acts through <strong>multiple mechanisms</strong>, including<strong> blocking voltage-dependent sodium channels</strong> and <strong>enhancing</strong> <strong>GABA activity, </strong>but<strong> not </strong>specifically through <strong>opening potassium channels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Retigabine</strong> is notable for<strong> its mechanism as a neuronal potassium channel opener, </strong>a <strong>distinct mode of action </strong>that differentiates it from other antiepileptic drugs. <strong>Major adverse effects</strong> to be aware of with<strong> retigabine include retinitis and blue pigmentation of the skin.</strong></span></span></p>",
    "correct_choice_id": 57853,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14499,
    "choices": [
      {
        "id": 57957,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Flumazenil</span></span></span></p>"
      },
      {
        "id": 57958,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Disulfiram</span></span></span></p>"
      },
      {
        "id": 57959,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Acamprosate </span></span></span></p>"
      },
      {
        "id": 57960,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Naltrexone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following drugs is not used in detoxification of patients with chronic alcohol use? </span></span></span></p>",
    "unique_key": "Q6071852",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457828,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Flumazenil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Flumazenil</strong> is an <strong>antagonist</strong> for<strong> benzodiazepine receptors </strong>and is primarily used to <strong>reverse the effects</strong> of <strong>benzodiazepines </strong>in cases of <strong>overdose</strong> or to<strong> hasten recovery after anesthesia</strong>. It <strong>does not</strong> have any role in the<strong> treatment or detoxification process </strong>for<strong> alcohol</strong> <strong>dependency</strong>. Its use is <strong>specific</strong> to the<strong> management of benzodiazepine-related emergencies.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Disulfiram:</span></strong><span style=\"font-size:12.0pt\"> Used as<strong> part of alcohol aversion therapy</strong>, <strong>disulfiram inhibits the enzyme acetaldehyde dehydrogenase,</strong> which leads to <strong>unpleasant effects</strong> when <strong>alcohol is consumed, </strong>thereby <strong>deterring</strong> the <strong>intake of alcohol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Acamprosate:</span></strong><span style=\"font-size:12.0pt\"> Helps <strong>reduce</strong> the<strong> craving and relapse</strong> in <strong>alcohol dependence </strong>by<strong> modulating neurotransmission </strong>via <strong>glutamate and GABA pathways.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Naltrexone:</span></strong><span style=\"font-size:12.0pt\"> Used as an<strong> anti-craving agent,</strong> <strong>naltrexone blocks opioid receptors</strong> that are part of the <strong>reward system</strong> affected by<strong> alcohol consumption.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While<strong> disulfiram, acamprosate, and naltrexone </strong>are <strong>directly</strong> involved in the <strong>treatment strategies for alcohol dependence </strong>to prevent <strong>relapse and manage cravings</strong>, <strong>flumazenil&#39;s </strong>application is<strong> restricted to benzodiazepine reversal,</strong> underscoring the<strong> </strong>importance of understanding<strong> specific drug roles in addiction therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs Used in Acute Ethanol Withdrawal </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Benzodiazepines</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (chlordiazepoxide, diazepam, lorazepam): They facilitate<strong> GABA-mediated activation of GABA receptors. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thiamine</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (vitamin B1): <strong>Alcoholic patients</strong> are <strong>deficient in thiamine.</strong> Hence, it must be <strong>administered to patients </strong>suspected of having <strong>alcoholism</strong> (those<strong> exhibiting acute alcohol intoxication or alcohol withdrawal syndrome</strong>) to <strong>prevent Wernicke-Korsakoff syndrome. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs Used in Chronic Alcoholism (Alcohol dependence)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Naltrexone</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">:<strong> Competitive antagonist </strong>of<strong> opioid receptors</strong>. It <strong>reduces</strong> <strong>craving </strong>in alcoholics.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acamprosate</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: <strong>NMDA receptor antagonist &amp; GABAA agonist </strong>effects. It also <strong>reduces craving.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Topiramate</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This <strong>anticonvulsant drug </strong>is also<strong> effective in reducing craving</strong>. It potentiates the <strong>inhibitory effects of GABA</strong> but <strong>acts at</strong> a <strong>site different from BZD.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Disulfiram</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is an<strong> inhibitor of aldehyde dehydrogenase</strong> and therefore <strong>causes accumulation of aldehyde </strong>if <strong>alcohol is ingested. </strong>This results in<strong> troublesome symptoms</strong>, like<strong> facial flushing, nausea, dizziness, headache.</strong> It is used as a <strong>deterrent agent (aversion therapy)</strong> to<strong> reduce the consumption of alcohol</strong> in motivated individuals. </span></span></p>",
    "correct_choice_id": 57957,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14503,
    "choices": [
      {
        "id": 57973,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Administer sodium bicarbonate</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">.</span></span></span></p>"
      },
      {
        "id": 57974,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Consider hemodialysis</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">.</span></span></span></p>"
      },
      {
        "id": 57975,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Administer fomepizole</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">.</span></span></span></p>"
      },
      {
        "id": 57976,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">flumazenil.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old female presents to the emergency department with altered mental status and hypotension. Her electrocardiogram (ECG) shows wide QRS complexes and right axis deviation. She has a history of depression and is taking an antidepressant medication. What is the next best step in the management of this patient?</span></span></span></p>",
    "unique_key": "Q8201134",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457829,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">. <strong>A) Administer Sodium bicarbonate. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation suggests <strong>a tricyclic antidepressant (TCA) overdose,</strong> which is known to cause<strong> cardiotoxic effects </strong>such as <strong>wide QRS complexes</strong> due to <strong>sodium channel blockade.</strong> <strong>Administering sodium bicarbonate </strong>is an <strong>effective treatment</strong> as it <strong>helps</strong> to <strong>alkalinize the blood, counteracting the sodium channel-blocking</strong> effects of<strong> TCAs on the heart</strong>. This treatment helps to <strong>normalize</strong> <strong>QRS duration</strong> and <strong>mitigate</strong> the <strong>risk of arrhythmias, </strong>providing an<strong> immediate therapeutic benefit</strong> in <strong>acute TCA toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Consider hemodialysis:</span></strong><span style=\"font-size:12.0pt\"> While useful in <strong>certain poisonings,</strong> it is <strong>not</strong> the<strong> first-line treatment for TCA overdose </strong>and is generally <strong>reserved for severe cases.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Administer fomepizole:</span></strong><span style=\"font-size:12.0pt\"> This is used for<strong> methanol or ethylene glycol poisoning, not for TCA overdose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Administer flumazenil:</span></strong><span style=\"font-size:12.0pt\"> This is an<strong> antidote for benzodiazepine overdose</strong> and is<strong> not </strong>useful in cases of<strong> TCA overdose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sodium bicarbonate</strong> is crucial for managing <strong>TCA overdose</strong> due to its <strong>ability to quickly mitigate</strong> the <strong>cardiotoxic effects </strong>associated with this<strong> type of poisoning</strong>, emphasizing the<strong> importance of rapid and appropriate intervention</strong> in such<strong> emergencies.</strong></span></span></p>",
    "correct_choice_id": 57973,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14579,
    "choices": [
      {
        "id": 58277,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      },
      {
        "id": 58278,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pregabalin</span></span></span></p>"
      },
      {
        "id": 58279,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levetiracetam</span></span></span></p>"
      },
      {
        "id": 58280,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 35-year-old male presented to a hospital with focal seizures. His renal function was normal. Which of the following is the drug of choice for this patient? </span></span></span></p>",
    "unique_key": "Q4598242",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457830,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Carbamazepine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine (<strong>DOC</strong>) and oxcarbazepine (related drug), phenytoin, lamotrigine and levetiracetam are currently the <strong>first line drugs</strong> approved for the initial treatment of focal seizures, including those that secondarily generalize. Overall, they have very similar efficacy, but differences in pharmacokinetics and toxicity are the main determinants for use in each patient.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">An advantage of carbamazepine is that its metabolism follows first-order pharmacokinetics, and the relationship between drug dose, serum levels, and toxicity is linear.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Oxcarbazepine has the advantage of lesser enzyme induction (and thus drug interactions) than carbamazepine. However, it has more association with dilutional hyponatremia than carbamazepine. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine tends to be well-tolerated in terms of side effects. However, patients need to be particularly vigilant about the possibility of a skin rash during the initiation of therapy. This can be extremely severe and lead to Stevens-Johnson syndrome if unrecognized and if the medication is not discontinued immediately.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproic acid is an effective alternative for some patients with partial seizures, especially when the seizures secondarily generalize.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58280,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14599,
    "choices": [
      {
        "id": 58357,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SNRI</span></span></span></p>"
      },
      {
        "id": 58358,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NDRI</span></span></span></p>"
      },
      {
        "id": 58359,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Antihistaminic</span></span></span></p>"
      },
      {
        "id": 58360,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Anticholinergic</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tramadol acts on &micro; receptor as an agonist. Additionally, it also acts as: </span></span></span></p>",
    "unique_key": "Q9336520",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457831,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) SNRI</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In addition to acting as <strong>an agonist at the &micro;-opioid receptor, tramadol </strong>also has <strong>activity</strong> as a<strong> serotonin-norepinephrine</strong> <strong>reuptake inhibitor (SNRI). </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This <strong>dual mechanism of action</strong> provides <strong>analgesic effects</strong> beyond those <strong>produced by opioids alone. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Tramadol </strong>is <strong>not</strong> an <strong>NDRI (norepinephrine-dopamine reuptake inhibitor), antihistaminic, or anticholinergic.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58357,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14593,
    "choices": [
      {
        "id": 58333,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Psychosis</span></span></span></p>"
      },
      {
        "id": 58334,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Severe vomiting</span></span></span></p>"
      },
      {
        "id": 58335,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Arrhythmia</span></span></span></p>"
      },
      {
        "id": 58336,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Postural hypotension</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following adverse effects of Levodopa can be reduced by carbidopa except</span></span></p>",
    "unique_key": "Q7958063",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457832,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Psychosis</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Levodopa</strong> is a <strong>precursor of dopamine,</strong> a<strong> neurotransmitter</strong> that is depleted in <strong>Parkinson&#39;s disease.</strong> It is <strong>converted into dopamine</strong> in the <strong>brain,</strong> where it <strong>stimulates dopamine receptors</strong>, including<strong> D1 and D2 receptors. Levodopa</strong> is <strong>not</strong> a<strong> dopamine receptor agonist,</strong> but rather a <strong>precursor of dopamine</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbidopa</strong> is often <strong>co-administered</strong> with<strong> levodopa</strong> to prevent<strong> its peripheral breakdown</strong> and<strong> increase its availability </strong>in the<strong> brain. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbidopa</strong> is a <strong>peripheral dopa decarboxylase inhibitor</strong> that<strong> does not cross the blood-brain barrier.</strong> It helps to <strong>reduce</strong> the <strong>peripheral adverse effects of levodopa</strong>, such as <strong>nausea and vomiting,</strong> <strong>postural hypotension,</strong> and <strong>cardiac</strong> <strong>arrhythmias, </strong>by<strong> preventing its breakdown </strong>in the <strong>gastrointestinal tract. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, <strong>carbidopa</strong> <strong>does not </strong>directly affect <strong>levodopa&#39;s activity on dopamine receptors</strong> in the brain, which is thought to be responsible for the <strong>development of psychosis as an adverse effect</strong>. Therefore,<strong> carbidopa cannot</strong> <strong>reduce</strong> the risk of developing<strong> psychosis</strong> as an <strong>adverse effect of levodopa.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58333,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 14603,
    "choices": [
      {
        "id": 58373,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Felbamate</span></span></p>"
      },
      {
        "id": 58374,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methadone </span></span></p>"
      },
      {
        "id": 58375,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine </span></span></p>"
      },
      {
        "id": 58376,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diltiazem </span></span></p>"
      }
    ],
    "text": "<p style=\"margin-left:0; margin-right:0; text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the following drugs are NMDA receptor blockers except.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "unique_key": "Q8776061",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457833,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Diltiazem </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>N-methyl-D-aspartate (NMDA) receptors</strong> are <strong>ionotropic glutamate receptors</strong> found in the <strong>central nervous system (CNS).</strong> These <strong>receptors</strong> are involved in <strong>synaptic plasticity</strong>, which is the process by which<strong> neurons adapt</strong> and <strong>change their strength in response</strong> to <strong>stimuli, </strong>including<strong> learning and memory. </strong>The activation of <strong>NMDA receptors </strong>requires<strong> both glutamate and glycine or D-serine,</strong> as well as the removal of a <strong>magnesium ion </strong>that<strong> blocks the channel at resting membrane potentials.</strong> The<strong> influx of calcium ions</strong> through the <strong>open channel</strong> leads to the<strong> activation of various intracellular signalling pathways</strong>, which can have<strong> both beneficial and detrimental effects on neuronal function.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>NMDA receptor blockers</strong> are drugs that<strong> inhibit the activity of NMDA receptors</strong>. They can be classified as either<strong> competitive or non-competitive antagonists, </strong>depending on the <strong>mechanism of action</strong>. <strong>Competitive antagonists </strong>bind to the<strong> same site as the agonist,</strong> whereas <strong>non-competitive antagonists bind </strong>to a <strong>separate site on the receptor.</strong> <strong>Clinically useful drugs</strong> are all <strong>non-competitive NMDA</strong> <strong>antagonists.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">IMPORTANT NDMA RECEPTOR ANTAGONISTS:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">F</span></strong><span style=\"font-size:12.0pt\">inal:&nbsp;&nbsp; <strong>F</strong>elbamate, <strong>P</strong>hencyclidine</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">N</span></strong><span style=\"font-size:12.0pt\">: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>N</strong>itrous oxide</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">M</span></strong><span style=\"font-size:12.0pt\">:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>M</strong>ethadone, <strong>M</strong>emantine, <strong>M</strong>agnesium</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">D</span></strong><span style=\"font-size:12.0pt\">:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>D</strong>extromethorphan</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">A</span></strong><span style=\"font-size:12.0pt\">:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>A</strong>camprosate, <strong>A</strong>mantadine</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">R</span></strong><span style=\"font-size:12.0pt\">eceptor:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>R</strong>iluzole</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">K</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">nockout:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>K</strong>etamine and Es<strong>k</strong>etamine</span></span></p>",
    "correct_choice_id": 58376,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8129,
    "choices": [
      {
        "id": 32484,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Filgrastim</span></span></span></p>"
      },
      {
        "id": 32485,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oprelvekin</span></span></span></p>"
      },
      {
        "id": 32486,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Erythropoietin</span></span></span></p>"
      },
      {
        "id": 32487,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron dextran</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is given to treat thrombocytopenia secondary to anti-cancer therapy and is known to stimulate progenitor megakaryocytes?</span></span></span></p>",
    "unique_key": "Q3242885",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457854,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Oprelvekin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Oprelvekin</strong> is the correct answer because it is a <strong>recombinant form of interleukin-11 (IL-11) </strong>and is specifically used to treat <strong>thrombocytopenia</strong>, which is a d<strong>ecrease in the number of platelets in the blood,</strong> <strong>secondary to anticancer therapy. Oprelvekin</strong> works by <strong>stimulating the proliferation of megakaryocyte progenitor cells</strong>, which are the <strong>precursors to platelets,</strong> thus<strong> increasing platelet</strong> <strong>production</strong>. This mechanism <strong>directly addresses </strong>the condition of<strong> thrombocytopenia</strong> by enhancing the body&#39;s ability to produce <strong>platelets</strong>, making it an<strong> effective treatment </strong>option in this context.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Filgrastim:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Filgrastim is a <strong>granulocyte colony-stimulating factor (G-CSF) </strong>that is used to<strong> increase neutrophil counts</strong> in patients<strong> undergoing chemotherapy.</strong> It <strong>stimulates </strong>the production of<strong> white blood cells,</strong> not platelets, and is therefore <strong>used to treat </strong>or <strong>prevent neutropenia</strong>, not thrombocytopenia.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Erythropoietin:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Erythropoietin is a <strong>glycoprotein hormone</strong> that<strong> stimulates erythropoiesis, </strong>or <strong>red blood cell production,</strong> in the<strong> bone marrow</strong>. It is<strong> used to</strong> treat<strong> anemia,</strong> particularly in<strong> chronic kidney disease </strong>and in patients <strong>undergoing chemotherapy.</strong> It <strong>does not</strong> directly<strong> increase platelet counts.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Iron dextran:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Iron dextran is an<strong> intravenous iron supplement</strong> used to treat <strong>iron deficiency anemia. </strong>It <strong>does not </strong>stimulate the production of <strong>platelets or megakaryocyte progenitors</strong> and is<strong> not used </strong>to treat <strong>thrombocytopenia secondary to anticancer therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to understand the<strong> hematopoietic growth factors </strong>and their role in <strong>treatment </strong>options for <strong>adverse effects</strong> of<strong> anticancer drugs</strong>.&nbsp; and to recognize that <strong>oprelvekin</strong> is <strong>used for its ability to stimulate progenitor megakaryocytes</strong>, leading to an <strong>increase in platelet production. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hematopoietic Growth Factors:</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture3.jpg\" style=\"height:543px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 32485,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8140,
    "choices": [
      {
        "id": 32528,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is used for the treatment of anaemia due to chronic renal failure.</span></span></span></p>"
      },
      {
        "id": 32529,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It results in decrease in reticulocyte count.</span></span></span></p>"
      },
      {
        "id": 32530,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It decreases the requirement of blood transfusions.</span></span></span></p>"
      },
      {
        "id": 32531,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It can cause hypertension.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about erythropoietin is false?</span></span></span></p>",
    "unique_key": "Q6468086",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457855,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. It results in decrease in reticulocyte count.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Erythropoietin </strong>is a <strong>growth factor</strong> that <strong>stimulates erythropoiesis</strong> or<strong> red blood cell production.</strong> It is indeed used to <strong>treat anaemia</strong>, particularly the type caused by<strong> chronic renal failure</strong>. It should lead to an<strong> <em>increase</em> in reticulocyte count</strong> as it stimulates the <strong>bone</strong> <strong>marrow to produce more red blood cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>&nbsp;Correct.</strong> <strong>Erythropoietin</strong> is used to<strong> treat anaemia</strong> due to <strong>chronic renal failure </strong>because the<strong> kidneys</strong> in such patients <strong>do not</strong> produce enough <strong>endogenous erythropoietin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Correct.</strong> By <strong>stimulating red blood cell production,</strong> <strong>erythropoietin</strong> <strong>reduces</strong> the need for <strong>blood transfusions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Correct.</strong> <strong>Erythropoietin</strong> can sometimes cause <strong>hypertension </strong>as a <strong>side effect </strong>because of the<strong> increased red blood cell mass</strong> and <strong>possibly</strong> other <strong>mechanisms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Erythropoietin </strong>treatment should result in an <strong>increased reticulocyte count,</strong> reflecting the <strong>stimulated production of red blood cells</strong>. It is <strong>beneficial in chronic renal failure-related anaemia </strong>and can help <strong>decrease </strong>the need for <strong>transfusions,</strong> although it may cause <strong>hypertension </strong>as a<strong> side effect.</strong></span></span></span></p>",
    "correct_choice_id": 32529,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8080,
    "choices": [
      {
        "id": 32288,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intramuscular</span></span></span></p>"
      },
      {
        "id": 32289,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subcutaneous</span></span></span></p>"
      },
      {
        "id": 32290,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intravenous</span></span></span></p>"
      },
      {
        "id": 32291,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhalational</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 65-year-old patient, with a history of hypertension and type 2 diabetes, recently underwent total hip replacement surgery. Post-operatively, the healthcare team is focused on preventing venous thromboembolism (VTE), a common complication after such surgeries. Given the patient&#39;s increased risk for VTE due to surgery, immobility, and underlying conditions, the decision to initiate thromboprophylaxis with low molecular weight (LMW) heparin was made. Route of administration of LMW heparin in this patient is</span></span></span></p>",
    "unique_key": "Q1803786",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457856,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Subcutaneous</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Low molecular weight (LMW) heparin</strong> is administered <strong>subcutaneously for thromboprophylaxis in post-operative patients.</strong> This route is preferred because it provides a<strong> reliable and consistent absorption,</strong> leading to <strong>predictable anticoagulant effects.</strong> <strong>Subcutaneous </strong>administration is particularly suitable for the<strong> prophylaxis of venous thromboembolism (VTE)</strong> in patients who have <strong>undergone surgeries </strong>such as<strong> total hip replacement, </strong>as it can be given <strong>outside of a hospital setting, does not </strong>require frequent <strong>monitoring of anticoagulation levels</strong>, and has a <strong>lower risk of hematoma</strong> compared to<strong> intramuscular injections.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Intramuscular:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> LMW heparin</strong> is <strong>not </strong>administered <strong>intramuscularly</strong> due to the<strong> risk of hematoma formation in the muscle,</strong> which can be particularly problematic in patients with a<strong> heightened risk of bleeding</strong> or those who are <strong>receiving anticoagulation</strong> <strong>therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Intravenous:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While<strong> LMW heparin</strong> can be <strong>administered intravenously,</strong> this route is<strong> not </strong>typically used for <strong>thromboprophylaxis</strong> in the<strong> post-operative setting.</strong> Intravenous administration is more common for <strong>unfractionated heparin,</strong> which requires<strong> monitoring of the anticoagulant effect</strong> and is used in <strong>acute settings.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inhalational:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This route is<strong> not</strong> <strong>applicable to LMW heparin</strong> as it i<strong>s not designed for inhalation. </strong>The <strong>inhalational</strong> route of administration is used for <strong>drugs</strong> intended to<strong> act directly on the lungs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to understand the<strong> appropriate route of administration for low molecular weight heparin </strong>in the context of<strong> thromboprophylaxis in post-operative patients</strong>. <strong>Subcutaneous </strong>administration is the<strong> preferred and recommended route </strong>because it offers <strong>consistent absorption and effective prevention </strong>of <strong>VTE without </strong>the need for routine<strong> anticoagulation monitoring</strong>, <strong>minimizing the risk of complications </strong>associated with<strong> other routes of administration.</strong></span></span></span></p>",
    "correct_choice_id": 32289,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8097,
    "choices": [
      {
        "id": 32356,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protamine sulphate</span></span></span></p>"
      },
      {
        "id": 32357,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin K</span></span></span></p>"
      },
      {
        "id": 32358,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tranexamic acid</span></span></span></p>"
      },
      {
        "id": 32359,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Factor VIII concentrate</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following drugs is used postoperatively to reverse the effect of heparin used intraoperatively in cardiac surgery?</span></span></span></p>",
    "unique_key": "Q3408072",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457857,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Protamine sulphate </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Protamine sulphate </strong>is a drug that is used to <strong>neutralize the anticoagulant effects of heparin, </strong>which is a<strong> negatively charged molecule.</strong> <strong>Protamine</strong>, being<strong> positively charged, </strong>binds to<strong> heparin, </strong>forming a <strong>complex that inhibits heparin&#39;s activity,</strong> effectively <strong>reversing its</strong> <strong>effects</strong>. This is particularly important in the <strong>context of cardiac surgery, </strong>where<strong> heparin</strong> is commonly used to<strong> prevent clot formation</strong> <strong>during the procedure.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Vitamin K:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong> because<strong> Vitamin K</strong> is used to <strong>reverse the effects of warfarin</strong>, not heparin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Tranexamic acid:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as it is used to <strong>reduce bleeding by inhibiting fibrinolysis, </strong>not reversing heparin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Factor VIII concentrate:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect </strong>as it is used in the <strong>treatment of hemophilia A, </strong>not for reversing heparin effects.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Protamine sulphate</strong> is the <strong>drug of choice</strong> for <strong>reversing the anticoagulant effects of heparin</strong> following<strong> cardiac surgeries</strong> or other <strong>procedures </strong>where <strong>heparin has been used</strong>. It works by<strong> binding to and neutralizing heparin.</strong></span></span></span></p>",
    "correct_choice_id": 32356,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8171,
    "choices": [
      {
        "id": 32652,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Isoniazid</span></span></span></p>"
      },
      {
        "id": 32653,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amiodarone</span></span></span></p>"
      },
      {
        "id": 32654,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carbamazepine</span></span></span></p>"
      },
      {
        "id": 32655,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cimetidine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs increase bleeding when given to a patient on warfarin except?</span></span></span></p>",
    "unique_key": "Q5202963",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457858,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Carbamazepine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Carbamazepine</strong> is an<strong> enzyme inducer and increases the metabolism of warfarin</strong>. This will<strong> reduce the action of warfarin,</strong> <strong>decreasing</strong> the <strong>risk of bleeding.</strong> <strong>All other drugs</strong> given in the options<strong> increase the risk of bleeding with warfarin</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Isoniazid:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Isoniazid is an<strong> inhibitor of CYP2C9</strong>, which can<strong> inhibit the metabolism of warfarin.</strong> This<strong> inhibition leads to</strong> <strong>increased plasma concentration of warfarin</strong>, thereby <strong>increasing the risk of bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Amiodarone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amiodarone is also an<strong> inhibitor of CYP2C9.</strong> Like isoniazid, it<strong> inhibits the metabolism of warfarin,</strong> leading to <strong>increased plasma concentration</strong> and an<strong> increased risk of bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Cimetidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Cimetidine</strong> is yet another<strong> inhibitor of CYP2C9.</strong> As with<strong> isoniazid and amiodarone, </strong>it<strong> inhibits the metabolism</strong> of<strong> warfarin,</strong> resulting in<strong> elevated plasma concentrations</strong> and an<strong> increased </strong>likelihood of<strong> bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Carbamazepine, </strong>as an<strong> enzyme inducer, decreases</strong> the <strong>plasma concentration of warfarin, reducing </strong>the <strong>risk of bleeding</strong> when<strong> used</strong> <strong>concomitantly.</strong></span></span><strong> </strong></span></span></span></p>",
    "correct_choice_id": 32654,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8184,
    "choices": [
      {
        "id": 32704,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enoxaparin</span></span></span></p>"
      },
      {
        "id": 32705,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Argatroban</span></span></span></p>"
      },
      {
        "id": 32706,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
      },
      {
        "id": 32707,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fondaparinux</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following anticoagulant therapy needs regular monitoring? </span></span></span></p>",
    "unique_key": "Q1909165",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457859,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Argatroban</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Argatroban </strong>requires <strong>regular monitoring</strong> because it is a <strong>direct thrombin inhibitor. </strong>It is used in patients with <strong>heparin-induced</strong> <strong>thrombocytopenia (HIT) </strong>and has a <strong>narrow therapeutic window</strong>, meaning the <strong>dosage and therapeutic effect</strong> must be <strong>carefully</strong> <strong>balanced </strong>to <strong>avoid under- or over-anticoagulation</strong>. <strong>Monitoring </strong>is <strong>typically done</strong> using the<strong> activated partial thromboplastin time (aPTT)</strong> to ensure the<strong> drug&#39;s efficacy and safety.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Enoxaparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Enoxaparin is a<strong> low molecular weight heparin </strong>(LMWH) used for the <strong>prevention and treatment of deep vein</strong> <strong>thrombosis (DVT) and pulmonary embolism (PE).</strong> While it has a <strong>mor</strong>e predictable <strong>dose-response</strong> relationship compared to <strong>unfractionated heparin</strong>, routine<strong> laboratory monitoring </strong>for anticoagulation effect is generally <strong>not required in most patients.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Dabigatran:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dabigatran is a <strong>direct oral anticoagulant (DOAC)</strong> that<strong> inhibits thrombin.</strong> It is <strong>used </strong>for <strong>stroke prevention</strong> in <strong>non-valvular atrial fibrillation </strong>and<strong> treatment of DVT </strong>and <strong>PE,</strong> among other indications.<strong> Dabigatran</strong> offers the advantage of<strong> fixed dosing without</strong> the need for<strong> routine coagulation monitoring.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fondaparinux:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fondaparinux is a <strong>synthetic pentasaccharide</strong> that<strong> inhibits factor Xa indirectly </strong>by <strong>binding to antithrombin</strong>. It is used for<strong> DVT prevention and treatment</strong> and for<strong> preventing PE. Like LMWH, fondaparinux</strong> generally <strong>does not </strong>require <strong>routine</strong> <strong>monitoring</strong> due to its predictable pharmacokinetic profile.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to<strong> understand</strong> which <strong>anticoagulant therapies</strong> require<strong> regular monitoring </strong>and which<strong> does not. </strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture6.jpg\" style=\"height:409px; width:1000px\" /></span></span></p>",
    "correct_choice_id": 32705,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8228,
    "choices": [
      {
        "id": 32879,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban</span></span></span></p>"
      },
      {
        "id": 32880,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Argatroban</span></span></span></p>"
      },
      {
        "id": 32881,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
      },
      {
        "id": 32882,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bivalirudin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is orally active direct Xa inhibitor? </span></span></span></p>",
    "unique_key": "Q8061906",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457860,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Rivaroxaban</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Rivaroxaban</strong> is an<strong> orally active direct Factor Xa inhibitor.</strong> It works by<strong> selectively inhibiting Factor Xa,</strong> an important enzyme in the <strong>coagulation cascade </strong>that<strong> leads to the formation of thrombin</strong> and <strong>development of a clot.</strong> By <strong>inhibiting Factor Xa</strong>,<strong> rivaroxaban</strong> <strong>reduces</strong> the <strong>generation of thrombin and the subsequent formation of blood clots</strong>. It is used for the <strong>prevention and treatment</strong> of various<strong> thromboembolic disorders</strong>, including<strong> deep vein thrombosis (DVT), pulmonary embolism (PE), and</strong> <strong>stroke prevention</strong> in patients with <strong>non-valvular atrial fibrillation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option B. Argatroban</strong>: Argatroban is a<strong> direct thrombin inhibitor,</strong> not a Factor Xa inhibitor. It is administered<strong> intravenously </strong>and is <strong>used </strong>primarily in patients with <strong>heparin-induced thrombocytopenia (HIT).</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option C. Dabigatran:</strong> <strong>Dabigatran</strong> is also a<strong> direct thrombin inhibitor</strong> but <strong>differs from argatroban</strong> in that it is<strong> orally active</strong>. It is <strong>not</strong> a <strong>Factor Xa inhibitor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D. Bivalirudin:</strong> <strong>Bivalirudin</strong> is <strong>another direct thrombin inhibitor,</strong> used <strong>intravenously, </strong>particularly in patients undergoing <strong>percutaneous coronary intervention (PCI). </strong>It is<strong> not </strong>a<strong> Factor Xa inhibitor</strong> and <strong>not orally active.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to recognize the<strong> classification of anticoagulant drugs</strong>, specifically identifying <strong>rivaroxaban </strong>as an <strong>orally active direct Factor Xa inhibitor. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Classification of Anticoagulants</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture8.jpg\" style=\"height:466px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 32879,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8108,
    "choices": [
      {
        "id": 32400,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is a bleeding disorder caused by a deficiency of von Willebrand factor (vWF) </span></span></span></p>"
      },
      {
        "id": 32401,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is a rare condition that only occurs in patients with a history of thrombosis</span></span></span></p>"
      },
      {
        "id": 32402,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is caused by the formation of antibodies against platelet factor 4 (PF4) complexed with heparin.</span></span></span></p>"
      },
      {
        "id": 32403,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HIT is characterized by a normal platelet count and increased risk of bleeding.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is correct about heparin-induced thrombocytopenia (HIT)?</span></span></span></p>",
    "unique_key": "Q5755001",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457861,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. HIT is caused by the formation of antibodies against platelet factor 4 (PF4) complexed with heparin.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Heparin-induced thrombocytopenia (HIT) </strong>is an<strong> immune-mediated adverse effect</strong> of<strong> heparin therapy. </strong>It occurs when the<strong> immune</strong> <strong>system </strong>forms<strong> antibodies against a complex of heparin and platelet factor 4 (PF4).</strong> This immune reaction can<strong> activate platelets,</strong> leading to <strong>thrombocytopenia and an increased risk of thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect</strong>. <strong>HIT</strong> is<strong> not</strong> related to<strong> von Willebrand factor (vWF)</strong>; <strong>vWF deficiency</strong> causes<strong> von Willebrand disease,</strong> a <strong>different</strong> <strong>bleeding disorder.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>. <strong>HIT</strong> can occur in any<strong> patient receiving heparin, not </strong>just those with a <strong>history of thrombosis.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>. <strong>HIT</strong> is characterized by a<strong> decreased platelet count (thrombocytopenia)</strong>,<strong> not</strong> a<strong> normal count, </strong>and it is associated with an<strong> increased risk of thrombosis, not bleeding.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Heparin-induced thrombocytopenia (HIT)</strong> is a <strong>serious </strong>and potentially<strong> life-threatening condition </strong>characterized by the<strong> formation of</strong> <strong>antibodies </strong>to complexes formed between<strong> heparin and PF4,</strong> leading to <strong>platelet activation and an increased risk of thrombosis</strong> despite a<strong> decrease in platelet count</strong>. Management involves <strong>discontinuation of heparin and initiation of alternative anticoagulation </strong>with agents like<strong> direct thrombin inhibitors.</strong></span></span></span></p>",
    "correct_choice_id": 32402,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8166,
    "choices": [
      {
        "id": 32632,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
      },
      {
        "id": 32633,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Protamine</span></span></span></p>"
      },
      {
        "id": 32634,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alteplase</span></span></span></p>"
      },
      {
        "id": 32635,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epsilon aminocaproic acid</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is an antifibrinolytic agent?</span></span></span></p>",
    "unique_key": "Q7148093",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457862,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Epsilon aminocaproic acid</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Antifibrinolytic agents </strong>are drugs that help to<strong> prevent the breakdown of blood clots by inhibiting the activity of fibrinolytic enzymes.</strong> <strong>Epsilon aminocaproic acid (EACA) </strong>and<strong> tranexamic acid </strong>are <strong>antifibrinolytic agents </strong>that work by <strong>inhibiting the conversion of</strong> <strong>plasminogen to plasmin, </strong>which is responsible for the <strong>breakdown of fibrin clots.</strong> These are <strong>used to </strong>treat <strong>excessive bleeding</strong> as in <strong>heavy menstrual flow,</strong> in surgical settings, and <strong>to prevent bleeding </strong>in patients <strong>with hemophilia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Dabigatran</strong> is a <strong>direct thrombin inhibitor</strong> that <strong>prevents</strong> the formation of<strong> blood clots</strong> by<strong> inhibiting</strong> the<strong> activity of thrombin,</strong> a key enzyme in the clotting process.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Protamine </strong>is a medication used to <strong>reverse the effects of heparin</strong>. Protamine works by <strong>binding to heparin</strong>,<strong> neutralizing its</strong> <strong>anticoagulant effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Alteplase</strong> is a<strong> thrombolytic agent</strong> that works by <strong>converting plasminogen to plasmin, </strong>which <strong>breaks down fibrin clots</strong>. It is used in <strong>cases of acute MI and stroke.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Epsilon aminocaproic acid</strong> and<strong> tranexamic acid </strong>are <strong>antifibrinolytic agents</strong> that <strong>inhibit the conversion of plasminogen to plasmin, preventing the breakdown of fibrin clots.</strong></span></span></span></p>",
    "correct_choice_id": 32635,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8187,
    "choices": [
      {
        "id": 32716,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is slower acting than clopidogrel.</span></span></span></p>"
      },
      {
        "id": 32717,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is contraindicated in stroke.</span></span></span></p>"
      },
      {
        "id": 32718,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a reversible antagonist of ADP receptors.</span></span></span></p>"
      },
      {
        "id": 32719,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decrease the risk of bleeding.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements about prasugrel is true as compared to clopidogrel?</span></span></span></p>",
    "unique_key": "Q6614565",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457863,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. It is contraindicated in stroke.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prasugrel </strong>is an <strong>antiplatelet drug</strong> that <strong>inhibits ADP-mediated platelet activation </strong>and <strong>aggregation</strong> by <strong>irreversibly binding to P2Y12</strong> <strong>receptors on platelets. </strong>It is a<strong> thienopyridine</strong> that is converted to <strong>its active metabolite</strong> <strong>more rapidly </strong>than clopidogrel, leading to <strong>more potent and rapid platelet inhibition.</strong> Therefore, <strong>option A is incorrect.</strong> <strong>Prasugrel</strong> is <strong>indicated </strong>for the treatment of <strong>acute</strong> <strong>coronary syndromes (ACS)</strong> and <strong>in patients </strong>undergoing <strong>percutaneous coronary intervention (PCI).</strong> However, it is <strong>contraindicated </strong>in patients with a<strong> history of stroke or transient ischemic attack (TIA) </strong>due to an <strong>increased risk of bleeding</strong>. Therefore, <strong>option B </strong>is the c<strong>orrect answer</strong>. Both prasugrel and clopidogrel <strong>irreversibly</strong> bind to <strong>P2Y12 receptors on platelets,</strong> making them <strong>irreversible</strong> antagonists. Therefore, <strong>option C is incorrect. Prasugrel </strong>has been associated with an <strong>increased risk of bleeding </strong>compared to <strong>clopidogrel</strong>, especially in patients with a<strong> history of stroke or TIA</strong>. Therefore, <strong>option D is</strong> <strong>also incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is <strong>slower acting </strong>than clopidogrel:<strong> Prasugrel</strong> is actually <strong>converted to its active metabolite</strong> <strong>more rapidly</strong> than clopidogrel, leading to<strong> more potent </strong>and<strong> rapid platelet inhibition</strong>. Therefore, this statement is<strong> incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is a <strong>reversible antagonist</strong> of <strong>ADP receptors:</strong> <strong>Prasugrel, like clopidogrel</strong>, is an<strong> irreversible antagonist </strong>of <strong>ADP receptors on</strong> <strong>platelets</strong>. It forms a <strong>covalent bond with the P2Y12 receptor,</strong> resulting in<strong> irreversible inhibition</strong> of <strong>platelet aggregation. </strong>Thus, this statement is<strong> incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Decrease </strong>the<strong> risk of bleeding</strong>:<strong> Prasugrel</strong> has been associated with an<strong> increased risk of bleeding</strong> compared to <strong>clopidogrel,</strong> especially in <strong>certain patient populations</strong>. Therefore, this statement is<strong> incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Prasugrel </strong>is <strong>contraindicated in patients</strong> with a<strong> history of stroke or transient ischemic attack (TIA) </strong>due to an <strong>increased risk of bleeding.</strong></span></span></span></span></span></p>",
    "correct_choice_id": 32717,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8272,
    "choices": [
      {
        "id": 33055,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stop warfarin and start heparin.</span></span></span></p>"
      },
      {
        "id": 33056,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stop warfarin and start heparin plus aspirin.</span></span></span></p>"
      },
      {
        "id": 33057,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Continue warfarin and add heparin.</span></span></span></p>"
      },
      {
        "id": 33058,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Switch to aspirin.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-week pregnant female was taking warfarin for prosthetic heart valves and has INR value of 3. Next step in the management is? </span></span></span></p>",
    "unique_key": "Q8130860",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457864,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Stop warfarin and start heparin.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>pregnant patient </strong>with a <strong>mechanical heart valve,</strong> <strong>warfarin </strong>poses a <strong>risk to the fetus,</strong> especially in the <strong>first trimester </strong>due to <strong>teratogenicity </strong>and in the <strong>last trimester due to the risk of fetal bleeding.</strong> The approach<strong> close to delivery </strong>is to<strong> switch from warfarin</strong> to <strong>heparin</strong> (either <strong>unfractionated heparin or low molecular weight heparin</strong>), which <strong>does not cross</strong> the <strong>placenta </strong>and therefore<strong> does</strong> <strong>not carry</strong> the same <strong>risks to the fetus.</strong> An<strong> INR of 3</strong> indicates that the patient is<strong> adequately anticoagulated, </strong>but transitioning to <strong>heparin is recommended</strong> as the<strong> patient </strong>approaches term to <strong>reduce the risk of bleeding</strong> <strong>during labor and delivery.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Stop warfarin and start heparin plus aspirin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Aspirin </strong>is an<strong> antiplatelet agent </strong>and is <strong>not </strong>typically required in the context of <strong>prosthetic heart valve </strong>management during pregnancy. Its addition could <strong>increase the risk of bleeding without</strong> providing clear <strong>additional benefit </strong>in this setting.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Continue warfarin and add heparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Continuing warfarin is<strong> not recommended close to delivery</strong> due to the <strong>risks</strong> mentioned above. The <strong>goal is</strong> to <strong>switch to heparin </strong>solely.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Switch to aspirin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Aspirin</strong> alone is<strong> insufficient</strong> for the management of <strong>thromboembolic risk in patients </strong>with<strong> prosthetic</strong> <strong>heart valves. Anticoagulation with heparin is necessary.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to recognize the<strong> importance of transitioning from warfarin to heparin in pregnant patients</strong> with <strong>mechanical heart valves</strong> as they approach<strong> delivery. Warfarin is contraindicated</strong> close to delivery due to the <strong>risk of fetal hemorrhage,</strong> and<strong> heparin </strong>is the preferred <strong>anticoagulant</strong> because it <strong>does not cross the placenta</strong>. This transition <strong>minimizes the risk of</strong> <strong>thromboembolism </strong>associated with the<strong> prosthetic valve</strong> and <strong>reduces</strong> the potential for <strong>bleeding complications </strong>during <strong>labor and</strong> <strong>delivery.</strong></span></span></p>",
    "correct_choice_id": 33055,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8147,
    "choices": [
      {
        "id": 32556,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostacyclin</span></span></span></p>"
      },
      {
        "id": 32557,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PGF 2&alpha;</span></span></span></p>"
      },
      {
        "id": 32558,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thromboxane A2</span></span></span></p>"
      },
      {
        "id": 32559,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phospholipase C</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Platelet aggregation is blocked by aspirin due to its action on: </span></span></span></p>",
    "unique_key": "Q6662670",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457865,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Thromboxane A2</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aspirin</strong> works by<strong> irreversibly inhibiting the enzyme cyclooxygenase-1 (COX-1) in platelets, </strong>which is crucial for the <strong>synthesis of</strong> <strong>thromboxane A2</strong>, a substance that <strong>stimulates platelets to aggregate</strong> and <strong>arteries to constrict.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Incorrect</strong>.<strong> Prostacyclin (PGI2) </strong>is an <strong>anti-aggregatory prostaglandin</strong> produced by <strong>endothelial cells</strong>, and <strong>aspirin </strong>actually helps to<strong> prevent thrombosis</strong> partly by<strong> not</strong> significantly affecting<strong> prostacyclin production.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Incorrect. PGF 2&alpha; (Prostaglandin F2 alpha)</strong> is<strong> not</strong> a major target of<strong> aspirin</strong> in the context of <strong>antiplatelet therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D: Incorrect.</strong> <strong>Phospholipase C</strong> is <strong>not</strong> inhibited by<strong> aspirin</strong>; aspirin <strong>targets COX enzymes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Aspirin</strong> <strong>blocks platelet aggregation</strong> by<strong> inhibiting the production of thromboxane A2</strong> through<strong> irreversible acetylation of the COX-1</strong> <strong>enzyme in platelets</strong>, affecting their <strong>function</strong> for the remainder of <strong>their lifespan.</strong></span></span><strong> </strong></span></span></span></p>",
    "correct_choice_id": 32558,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8177,
    "choices": [
      {
        "id": 32676,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteophysin</span></span></span></p>"
      },
      {
        "id": 32677,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteotensin</span></span></span></p>"
      },
      {
        "id": 32678,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteocalcin</span></span></span></p>"
      },
      {
        "id": 32679,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteogenin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warfarin embryopathy is due to the action of? </span></span></span></p>",
    "unique_key": "Q4998383",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457866,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Osteocalcin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin embryopathy </strong>refers to a constellation of<strong> developmental abnormalities </strong>in<strong> fetuses </strong>exposed to<strong> warfarin during pregnancy.</strong> The mechanism underlying <strong>warfarin embryopathy</strong> involves<strong> interference with the vitamin K-dependent carboxylation of osteocalcin,</strong> a<strong> bone matrix protein </strong>crucial for<strong> proper bone development.</strong> <strong>Osteocalcin</strong>, when <strong>carboxylated,</strong> plays a role in<strong> bone</strong> <strong>mineralization and matrix formation</strong>.<strong> Warfarin inhibits</strong> the enzyme <strong>vitamin K epoxide reductase,</strong> leading to <strong>decreased levels of</strong> <strong>reduced vitamin K</strong>, which is necessary for the <strong>carboxylation of osteocalcin. </strong>Consequently, <strong>impaired carboxylation</strong> of<strong> osteocalcin</strong> results in<strong> skeletal abnormalities </strong>characteristic of <strong>warfarin embryopathy,</strong> such as <strong>nasal hypoplasia,</strong> stippled epiphyses, and <strong>long bone deformities.</strong> Thus, the<strong> action of warfarin</strong> causing<strong> embryopathy</strong> is primarily mediated through its <strong>interference with osteocalcin</strong> <strong>carboxylation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Osteophysin: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">There is<strong> no </strong>known substance called<strong> osteophysin</strong>. It <strong>does not </strong>play a role in<strong> warfarin embryopathy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Osteotensin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Osteotensin</strong> is <strong>not </strong>associated <strong>with warfarin embryopathy.</strong> It is<strong> not</strong> a <strong>recognized factor</strong> involved in<strong> bone</strong> <strong>development</strong> or the <strong>effects of warfarin </strong>on<strong> fetal development.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Osteogenin: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Osteogenin,</strong> also known as <strong>bone morphogenetic protein-3 (BMP-3),</strong> is a<strong> protein</strong> involved in <strong>bone formation</strong> <strong>and development</strong>. However, it is<strong> not</strong> implicated in the <strong>mechanism of warfarin embryopathy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin embryopathy</strong> results from the <strong>inhibition of vitamin K-dependent carboxylation of osteocalcin,</strong> a <strong>bone matrix protein</strong> essential for <strong>proper bone development during fetal life.</strong></span></span></p>",
    "correct_choice_id": 32678,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8207,
    "choices": [
      {
        "id": 32796,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ticlopidine</span></span></span></p>"
      },
      {
        "id": 32797,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tirofiban</span></span></span></p>"
      },
      {
        "id": 32798,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clopidogrel</span></span></span></p>"
      },
      {
        "id": 32799,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prasugrel</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are ADP inhibitors except:</span></span></span></p>",
    "unique_key": "Q2122889",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457867,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Tirofiban</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tirofiban</strong> is<strong> not</strong> an <strong>ADP inhibitor.</strong> It is a <strong>glycoprotein IIb/IIIa inhibitor</strong>, which<strong> prevents fibrinogen</strong> from <strong>binding to platelets,</strong> thereby <strong>inhibiting platelet aggregation. Tirofiban acts</strong> on a<strong> different pathway </strong>in the <strong>platelet aggregation process </strong>compared to <strong>ADP</strong> <strong>inhibitors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Ticlopidine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ticlopidine is an <strong>ADP receptor inhibitor</strong> that <strong>inhibits platelet aggregation</strong> by<strong> blocking the P2Y12 ADP recepto</strong>r on the<strong> platelet surface,</strong> making it <strong>less responsive to stimuli </strong>that cause <strong>aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Clopidogrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Clopidogrel </strong>is also an <strong>ADP receptor inhibitor</strong>, similar to ticlopidine, that works by <strong>irreversibly inhibiting</strong> the <strong>P2Y12 subtype of the ADP receptor</strong> on platelets, thus <strong>reducing platelet aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Prasugrel:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Prasugrel is a third example of an <strong>ADP receptor inhibitor.</strong> It is a<strong> prodrug </strong>that, <strong>once metabolized,</strong> <strong>inhibits </strong>the <strong>P2Y12 ADP receptor on platelets</strong>, leading to <strong>decreased platelet aggregation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to <strong>identify the classification of antiplatelet drugs,</strong> specifically distinguishing<strong> ADP receptor inhibitors</strong> <strong>(ticlopidine, clopidogrel, and prasugrel)</strong> from <strong>other classes </strong>such as <strong>glycoprotein IIb/IIIa inhibitors (tirofiban). </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antiplatelet Drugs</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture7.jpg\" style=\"height:500px; width:1000px\" /></p>",
    "correct_choice_id": 32797,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8236,
    "choices": [
      {
        "id": 32911,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Warfarin</span></span></span></p>"
      },
      {
        "id": 32912,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran</span></span></span></p>"
      },
      {
        "id": 32913,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban</span></span></span></p>"
      },
      {
        "id": 32914,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Heparin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old patient was started on anticoagulant therapy for DVT. Few days after he presented to emergency with the features as shown in figure. Which could be the culprit drug?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/picture9.jpg\" style=\"height:142px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q6336489",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457868,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Warfarin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The figure shows the clinical picture of <strong>dermal vascular necrosis</strong>, also known as<strong> &lsquo;purple toe syndrome.&rsquo;</strong> It is an<strong> early adverse effect</strong> of<strong> warfarin therapy</strong>. This condition is seen in patients with <strong>genetic protein C deficiency.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dermal Vascular Necrosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong> Warfarin-induced dermal vascular necrosis </strong>is a<strong> rare </strong>complication of <strong>warfarin therapy</strong>. It is characterized by the development of <strong>painful skin lesions</strong> in patients taking<strong> warfarin. I</strong>t is thought to be <strong>caused by a transient hypercoagulable state</strong> resulting from a<strong> rapid reduction in protein C levels </strong>in patients with<strong> underlying protein C deficiency </strong>or other risk factors. The lesions typically<strong> occur </strong>in areas with a<strong> high concentration of adipose tissue, </strong>such as the<strong> breasts, thighs, and buttocks</strong>. The initial symptoms include <strong>red or purple spots on the skin</strong><strong> </strong>that can<strong> quickly progress to painful, necrotic lesions </strong>with a <strong>central blister </strong>or <strong>eschar.</strong> The<strong> diagnosis </strong>is usually made <strong>clinically</strong> based on the <strong>characteristic appearance of the lesions </strong>and the <strong>patient&#39;s history of</strong> <strong>warfarin therapy.</strong> The treatment of <strong>dermal vascular necrosis</strong> involves<strong> stopping warfarin </strong>and <strong>initiating alternative anticoagulant</strong> therapy, such as <strong>heparin or low molecular weight heparin.</strong> In <strong>severe cases, surgical intervention</strong> may be necessary to<strong> remove</strong> the <strong>necrotic tissue and prevent further damage.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Dabigatran: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dabigatran is a <strong>direct thrombin inhibitor</strong> and is <strong>not associated with dermal vascular necrosis</strong>. It<strong> does not</strong> <strong>affect protein C levels</strong> or lead to <strong>hypercoagulable states</strong> like<strong> warfarin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Rivaroxaban: </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rivaroxaban is a<strong> factor Xa inhibitor</strong> and is<strong> not </strong>associated with <strong>dermal vascular necrosis</strong>. Like dabigatran, it <strong>does not </strong>affect<strong> protein C levels</strong> or<strong> lead to hypercoagulable states</strong> like<strong> warfarin.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Heparin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Heparin</strong> is a different class of<strong> anticoagulant </strong>and is <strong>not</strong> associated with <strong>dermal vascular necrosis</strong>. It works by <strong>enhancing the activity of antithrombin III </strong>and<strong> inhibiting </strong>the<strong> coagulation cascade at multiple points.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Warfarin-induced dermal vascular necrosis,</strong> also known as <strong>&#39;purple toe syndrome,&#39;</strong> is a <strong>rare</strong> complication of<strong> warfarin therapy </strong>seen in patients with<strong> genetic protein C deficiency</strong>. <strong>Prompt recognition and management</strong> are <strong>essential to prevent further complications.</strong></span></span></span></span></span></p>",
    "correct_choice_id": 32911,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10860,
    "choices": [
      {
        "id": 43406,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of leukotriene D4 receptor</span></span></span></p>"
      },
      {
        "id": 43407,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of 5-lipoxygenase</span></span></span></p>"
      },
      {
        "id": 43408,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antagonism of muscarinic receptors</span></span></span></p>"
      },
      {
        "id": 43409,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of phosphodiesterase</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old female patient with a history of asthma presents to the clinic with worsening shortness of breath, cough, and wheezing. Her asthma is typically well-controlled with inhaled glucocorticoids and short-acting beta-2 agonists as needed, but she reports increased symptoms over the past several days. The patient is started on montelukast as an adjunct therapy. What is the mechanism of action of montelukast?</span></span></span></p>",
    "unique_key": "Q2330960",
    "question_audio": null,
    "question_video": null,
    "map_id": 15457999,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A. Inhibition of leukotriene D4 receptor.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Montelukast</strong> works by <strong>selectively inhibiting the leukotriene D4 receptor,</strong> part of the pathway that <strong>leads to inflammation,</strong> <strong>bronchoconstriction,</strong> and <strong>mucus production in asthma.</strong> By blocking the <strong>action of leukotrienes</strong>, <strong>montelukast reduces airway edema,</strong> <strong>smooth muscle contraction, and inflammation, </strong>making it an <strong>effective controller medication</strong> for <strong>chronic asthma management </strong>and for<strong> preventing exercise-induced bronchospasm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Inhibition of 5-lipoxygenase:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the <strong>action of drugs like zileuton</strong>, not montelukast, and involves <strong>stopping leukotriene</strong> <strong>synthesis</strong> at an earlier stage in the pathway.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Antagonism of muscarinic receptors:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically associated with <strong>anticholinergic drugs like ipratropium</strong>, which are used to <strong>relax airway smooth muscles</strong> via a<strong> different mechanism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Inhibition of phosphodiesterase:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Associated with drugs like <strong>theophylline</strong>, which<strong> increase cAMP levels </strong>in<strong> smooth muscle</strong> <strong>cells, leading to bronchodilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Montelukast blocks leukotriene D4 receptors, </span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">crucial for managing </span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">chronic asthma and preventing exercise-induced bronchospasm.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This mechanism highlights its role beyond <strong>immediate symptom relief, focusing on long-term asthma control.</strong></span></span></span></span></span></p>",
    "correct_choice_id": 43406,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10847,
    "choices": [
      {
        "id": 43354,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac failure</span></span></span></p>"
      },
      {
        "id": 43355,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchial asthma</span></span></span></p>"
      },
      {
        "id": 43356,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic failure</span></span></span></p>"
      },
      {
        "id": 43357,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Arthritis</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of 5-lipoxygenase is useful in. </span></span></span></p>",
    "unique_key": "Q9438754",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458000,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Bronchial asthma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>5-lipoxygenase</strong> is a crucial enzyme involved in the <strong>production of leukotrienes</strong>, <strong>potent inflammatory mediators</strong> significantly involved in the <strong>pathophysiology of bronchial asthma</strong>. I<strong>nhibiting</strong> this <strong>enzyme reduces leukotriene production</strong>, effectively <strong>decreasing</strong> <strong>inflammation and improving symptoms in asthma </strong>patients. Drugs like <strong>zileuton target 5-lipoxygenase, </strong>highlighting its specific use in managing asthma by<strong> controlling leukotriene-driven inflammatory processes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cardiac failure:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> There is <strong>no</strong> established <strong>use of 5-lipoxygenase inhibitors</strong> in the treatment of <strong>cardiac failure, as leukotrienes</strong> <strong>do not</strong> play a significant role in this condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hepatic failure:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Similarly,<strong> inhibiting 5-lipoxygenase </strong>is<strong> not a</strong> therapeutic approach in<strong> hepatic failure,</strong> where <strong>leukotrienes</strong> are <strong>not</strong> a primary concern.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Arthritis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Although <strong>leukotrienes contribute to inflammation, 5-lipoxygenase inhibitors</strong> are <strong>not</strong> commonly used in <strong>arthritis</strong>. Other <strong>anti-inflammatory drugs</strong> are preferred for their<strong> broader efficacy in treating joint inflammation and pain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>5-lipoxygenase inhibition</strong> is specifically<strong> beneficial in asthma </strong>management <strong>due to its role</strong> in <strong>reducing leukotriene production,</strong> a key <strong>component of the inflammatory response in asthma.</strong></span></span></p>",
    "correct_choice_id": 43355,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10849,
    "choices": [
      {
        "id": 43362,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antagonize leukotriene D4 receptor.</span></span></span></p>"
      },
      {
        "id": 43363,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibits 5-lipoxygenase.</span></span></span></p>"
      },
      {
        "id": 43364,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibit phosphodiesterase&rsquo;s.</span></span></span></p>"
      },
      {
        "id": 43365,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stimulate beta 2 receptors.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 34-year-old man with a long history of asthma is referred to pulmonologist. The physician decides to prescribe zileuton. The mechanism of action of this drug is to?</span></span></span></p>",
    "unique_key": "Q8144755",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458001,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Inhibits 5- lipoxygenase.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Zileuton</strong> works by <strong>inhibiting 5-lipoxygenase</strong>, an enzyme involved in the <strong>synthesis of leukotrienes</strong>, which are key mediators in the <strong>inflammatory process associated with asthma. </strong>By <strong>reducing leukotriene production</strong>, zileuton <strong>decreases inflammation and</strong> <strong>respiratory symptoms in asthma patients</strong>, making it an <strong>effective treatment </strong>for managing <strong>chronic asthma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Antagonize leukotriene D4 receptor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the mechanism of<strong> leukotriene receptor antagonists like montelukast and</strong> <strong>zafirlukast, </strong>not zileuton.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Inhibit phosphodiesterase:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the <strong>action of drugs</strong> like <strong>theophylline,</strong> which are used as <strong>bronchodilators </strong>and <strong>anti-inflammatory agents </strong>but are unrelated to the mechanism of zileuton.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Stimulate beta 2 receptors:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This describes the<strong> action of beta-2 agonists </strong>such as<strong> salbutamol and terbutaline,</strong> which are used as <strong>rescue inhalers for acute asthma exacerbations.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Zileuton&#39;s ability</strong> to <strong>inhibit the 5-lipoxygenase enzyme</strong> and thus<strong> decrease leukotriene production</strong> is vital for its <strong>effectiveness in</strong> <strong>asthma management,</strong> <strong>targeting</strong> a specific part of the <strong>inflammatory pathway.</strong></span></span></span></span></span></p>",
    "correct_choice_id": 43363,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10848,
    "choices": [
      {
        "id": 43358,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Salbutamol</span></span></span></p>"
      },
      {
        "id": 43359,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ipratropium</span></span></span></p>"
      },
      {
        "id": 43360,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Montelukast</span></span></span></p>"
      },
      {
        "id": 43361,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The drug not used in acute asthma is. </span></span></span></p>",
    "unique_key": "Q9513901",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458002,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Montelukast</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Montelukast</strong>, a l<strong>eukotriene receptor antagonist</strong>, is primarily utilized for<strong> long-term control of asthma</strong> and to <strong>prevent exercise-induced bronchoconstriction. </strong>It is <strong>not</strong> suited for<strong> acute asthma management</strong> because it <strong>does not</strong> provide <strong>immediate</strong> <strong>bronchodilation, </strong>which is critical during an<strong> asthma attack. </strong>Its role in asthma management is <strong>preventative rather than responsive,</strong> making it <strong>ineffective in emergency situations </strong>where<strong> rapid symptom relief is necessary.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Salbutamol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a <strong>short-acting beta-2 agonist </strong>frequently used for<strong> immediate relief in acute asthma</strong> due to its <strong>rapid</strong> o<strong>nset of action in bronchodilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Ipratropium:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An <strong>anticholinergic used </strong>as an adjunct with<strong> beta-2 agonists </strong>for <strong>acute asthma exacerbations</strong>, providing <strong>additional bronchodilation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hydrocortisone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>systemic corticosteroid </strong>often used in<strong> acute asthma to reduce inflammation and improve symptoms,</strong> particularly in<strong> severe cases </strong>or those <strong>not responding adequately to bronchodilator</strong>s.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Montelukast</strong> is<strong> not </strong>used for <strong>acute asthma attacks</strong> due to its <strong>lack of rapid bronchodilatory effects</strong>, underscoring the importance of <strong>selecting</strong> appropriate medications for<strong> immediate versus long-term asthma management.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only <strong>bronchodilator drugs</strong> are <strong>useful </strong>for the treatment of<strong> acute attack of asthma.</strong> Main drugs are: </span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta 2 agonists e.g., salbutamol, terbutaline</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anticholinergics e.g., ipratropium, tiotropium</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methylxanthines e.g., theophylline </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In addition,<strong> steroids like hydrocortisone </strong>are used for the treatment of<strong> status asthmaticus. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other drugs used for asthma (like <strong>mast cell stabilizers, leukotriene receptor antagonists and lipoxygenase inhibitors</strong>) are<strong> indicated</strong> only for<strong> prophylaxis.</strong></span></span></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 43360,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10852,
    "choices": [
      {
        "id": 43374,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac arrhythmias</span></span></span></p>"
      },
      {
        "id": 43375,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diuresis</span></span></span></p>"
      },
      {
        "id": 43376,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Seizures</span></span></span></p>"
      },
      {
        "id": 43377,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GI discomfort</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All adverse effects of theophylline are mediated by A1 receptor except? </span></span></span></p>",
    "unique_key": "Q1364977",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458003,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. GI discomfort</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Theophylline&#39;s adverse effects such as <strong>cardiac arrhythmias, diuresis, and seizures </strong>are generally mediated by its <strong>action</strong> as an <strong>adenosine A1 receptor antagonist.</strong> This mechanism involves <strong>blocking adenosine&rsquo;s normal protective roles,</strong> which can<strong> lead to</strong> these <strong>effects</strong>. However, <strong>GI discomfort</strong>, including <strong>nausea and vomiting,</strong> is primarily caused by <strong>theophylline&rsquo;s inhibition</strong> of <strong>phosphodiesterase-4 (PDE-4), </strong>not by adenosine A1 receptor antagonism.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cardiac arrhythmias:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These are associated with <strong>adenosine A1 receptor antagonism</strong>, which can <strong>increase </strong>the likelihood of <strong>arrhythmias </strong>due to<strong> increased cardiac excitability.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Diuresis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Theophylline increases urine production</strong> partly through its<strong> antagonistic effects on adenosine A1 receptors, </strong>which <strong>normally promote sodium and water reabsorption.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Seizures:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also mediated by <strong>adenosine A1 receptor antagonism;</strong> <strong>adenosine</strong> typically has a <strong>neuroprotective role,</strong> and <strong>blocking its receptors</strong> increases seizure risk.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Side effects of theophylline and proposed mechanisms</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/09/picture2_UZNUPoT.jpg\" style=\"height:218px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 43377,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10853,
    "choices": [
      {
        "id": 43378,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beclomethasone</span></span></span></p>"
      },
      {
        "id": 43379,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Betamethasone</span></span></span></p>"
      },
      {
        "id": 43380,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Budesonide</span></span></span></p>"
      },
      {
        "id": 43381,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluticasone acetonide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not an inhalational corticosteroid?</span></span></span></p>",
    "unique_key": "Q1540177",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458004,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Betamethasone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Betamethasone </strong>is primarily used as a <strong>systemic corticosteroid</strong> and is typically <strong>administered orally or via injection.</strong> It is known for its <strong>potent anti-inflammatory effects</strong> but is<strong> not</strong> formulated as an <strong>inhalational corticosteroid </strong>for treating <strong>respiratory conditions like</strong> <strong>asthma</strong>. <strong>Inhalational corticosteroids </strong>are designed to deliver <strong>direct anti-inflammatory effects</strong> to the <strong>airways, minimizing systemic</strong> <strong>absorption </strong>and associated<strong> side effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Beclomethasone:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an <strong>inhalational corticosteroid </strong>commonly used in the management of <strong>asthma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Budesonide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also an <strong>inhalational corticosteroid,</strong> frequently used to <strong>control and prevent</strong> symptoms in <strong>asthma and COPD.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Fluticasone acetonide:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Utilized as an <strong>inhalational corticosteroid,</strong> effective in <strong>reducing airway inflammation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhalational Corticosteroids</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/09/picture3.jpg\" style=\"height:561px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 43379,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10861,
    "choices": [
      {
        "id": 43410,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Theophylline</span></span></span></p>"
      },
      {
        "id": 43411,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Omalizumab</span></span></span></p>"
      },
      {
        "id": 43412,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Zafirlukast</span></span></span></p>"
      },
      {
        "id": 43413,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Salbutamol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which anti-asthmatic drug X act through the mechanism as shown in figure:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/09/picture5_Kd14fvk.jpg\" style=\"height:578px; width:700px\" /></span></span></span></p>",
    "unique_key": "Q5462521",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458005,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Omalizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Omalizumab</strong> is a <strong>monoclonal antibody</strong> used for the treatment of<strong> moderate to severe asthma</strong> that <strong>isn&#39;t well-controlled</strong> with standard therapies. It works by <strong>binding to the Fc portion of IgE antibodies</strong>, <strong>preventing</strong> them from <strong>binding to receptors on mast cells</strong> <strong>and basophils</strong>. This mechanism <strong>blocks the allergic response, reducing inflammation and improving asthma symptoms</strong>. <strong>Omalizumab</strong> specifically targets th<strong>e immunologic aspect of asthma</strong> by<strong> modulating the allergic cascade</strong> that leads to <strong>asthma exacerbation</strong>s. By <strong>blocking the binding of IgE to its receptors</strong>, omalizumab can<strong> reduce the allergic response </strong>in the airways, which can help to <strong>reduce</strong> <strong>inflammation and improve asthma symptoms</strong>. Specifically, omalizumab can:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Reduce</strong> the release <strong>of inflammatory mediators from mast cells and basophils.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Reduce</strong> the recruitment of<strong> inflammatory cells to the airways.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Reduce</strong> the <strong>hyperresponsiveness of the airways</strong> to <strong>allergens and other triggers.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Theophylline:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Works by <strong>inhibiting phosphodiesterase and antagonizing adenosine receptors,</strong> leading to <strong>bronchodilation</strong> and some <strong>anti-inflammatory effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Zafirlukast:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A l<strong>eukotriene receptor antagonist</strong> that<strong> blocks </strong>the <strong>action of leukotrienes</strong> on their receptors, helping to <strong>control</strong> <strong>asthma symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Salbutamol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>short-acting beta-2 agonist</strong> that <strong>stimulates receptors</strong> to cause <strong>bronchodilation,</strong> providing <strong>quick relief </strong>from <strong>asthma symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Omalizumab targets IgE to prevent allergic reactions that can exacerbate asthma, representing a tailored approach to treating asthma influenced by allergies.</span></span></strong></span></span></span></p>",
    "correct_choice_id": 43411,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10862,
    "choices": [
      {
        "id": 43414,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Salbutamol</span></span></span></p>"
      },
      {
        "id": 43415,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphine</span></span></span></p>"
      },
      {
        "id": 43416,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Theophylline</span></span></span></p>"
      },
      {
        "id": 43417,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Steroids</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following drugs are used in treatment or prophylaxis of bronchial asthma except.</span></span></span></p>",
    "unique_key": "Q7477670",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458006,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B. Morphine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Morphine</strong> is generally <strong>avoided</strong> in <strong>asthma treatment </strong>because it can <strong>release histamine,</strong> which may <strong>provoke bronchospasm</strong> and <strong>worsen asthma symptoms</strong>. This characteristic makes it<strong> contraindicated for patients with asthma,</strong> especially<strong> during acute</strong> <strong>exacerbations.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Salbutamol:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Widely used as a <strong>rescue medication in asthma </strong>for its<strong> rapid bronchodilatory effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Theophylline:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>methylxanthine drug </strong>that provides<strong> bronchodilation </strong>by <strong>inhibiting phosphodiesterase</strong> and has <strong>some anti-inflammatory properties.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Steroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Essential for<strong> controlling chronic inflammation in asthma;</strong> used <strong>both in acute management </strong>and for <strong>long-term</strong> <strong>control.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Morphine can worsen asthma symptoms due to histamine release, making it unsuitable for asthma patients</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Drugs used in Asthma</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/09/picture6_BScoSQZ.jpg\" style=\"height:532px; width:1000px\" /><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/09/picture7_OMtFvT4.jpg\" style=\"height:349px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 43415,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10850,
    "choices": [
      {
        "id": 43366,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">They are used alone for the treatment of acute attacks of asthma.</span></span></span></p>"
      },
      {
        "id": 43367,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">They have high systemic activity.</span></span></span></p>"
      },
      {
        "id": 43368,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">They are superior to &beta;2 agonists in symptom control.</span></span></span></p>"
      },
      {
        "id": 43369,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Oral candidiasis can occur as a side effect.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Select the correct statement regarding use of inhaled glucocorticoids in bronchial asthma? </span></span></span></p>",
    "unique_key": "Q5522458",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458007,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D. Oral candidiasis can occur as a side effect.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Inhaled glucocorticoids</strong> are crucial for the <strong>long-term management of asthma </strong>due to their <strong>anti-inflammatory properties</strong>. One of the c<strong>ommon side effects</strong> of inhaled<strong> glucocorticoids is oral candidiasis.</strong> This <strong>fungal infection</strong> can develop due to the <strong>local</strong> <strong>immunosuppressive action of glucocorticoids in the mouth,</strong> <strong>fostering fungal growth</strong>.<strong> Proper inhaler technique</strong>, including <strong>mouth</strong> <strong>rinsing after use</strong>, is recommended to<strong> minimize this risk.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. They are used alone for the treatment of acute attacks of asthma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is <strong>incorrect </strong>as i<strong>nhaled glucocorticoids</strong> <strong>do not</strong> provide the<strong> immediate symptom relief </strong>required during an<strong> acute asthma attack.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. They have high systemic activity:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Inhaled glucocorticoids </strong>are designed to <strong>minimize systemic absorption</strong>, thus reducing s<strong>ystemic side effects</strong> compared to<strong> oral glucocorticoids.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. They are superior to &beta;2 agonists in symptom control:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is<strong> incorrect</strong> as <strong>&beta;2 agonists</strong> are the drugs of choice for <strong>immediate relief of symptoms</strong> due to their <strong>rapid bronchodilatory effects</strong>, whereas<strong> inhaled glucocorticoids</strong> are used for <strong>long-term</strong> <strong>control and prevention of symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The potential for <strong>developing oral candidiasis</strong> is a significant consideration when using<strong> inhaled glucocorticoids for asthma</strong> management, emphasizing the <strong>importance of proper inhaler use and oral hygiene practices</strong></span></span></span></span></span></p>",
    "correct_choice_id": 43369,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 10866,
    "choices": [
      {
        "id": 43430,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elderly patient</span></span></span></p>"
      },
      {
        "id": 43431,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Concomitant use of fluoroquinolones</span></span></span></p>"
      },
      {
        "id": 43432,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic smoker</span></span></span></p>"
      },
      {
        "id": 43433,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hepatic insufficiency</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following conditions warrant reduction in dose of theophylline in asthma except. </span></span></span></p>",
    "unique_key": "Q9419625",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458008,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C. Chronic smoker</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Theophylline</strong> is a <strong>bronchodilator</strong> that also has <strong>anti-inflammatory effects </strong>and can <strong>improve mucociliary clearance</strong>. It acts by<strong> inhibiting phosphodiesterase enzymes</strong>, leading to an <strong>increase in intracellular levels of cAMP, </strong>which results in <strong>bronchodilation.</strong> <strong>Chronic</strong> <strong>smokers </strong>may require<strong> higher doses of theophylline</strong> because <strong>smoking induces certain liver enzymes (specifically cytochrome P450</strong> enzymes), <strong>which increase the metabolism of theophylline</strong>. This induction necessitates a <strong>higher dose to achieve therapeutic drug levels</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Elderly patient:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Theophylline metabolism decreases</strong> with <strong>age</strong> due to<strong> reduced liver and kidney function.</strong> Elderly patients generally require <strong>lower doses to prevent toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Concomitant use of fluoroquinolones:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fluoroquinolones<strong> inhibit the metabolism of theophylline, </strong>which can <strong>lead to higher</strong> <strong>plasma concentrations </strong>and <strong>potential toxicity.</strong> Therefore, <strong>dose reductions</strong> are necessary when <strong>theophylline</strong> is used concurrently with <strong>fluoroquinolones.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hepatic insufficiency:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Liver disease</strong> significantly <strong>impairs theophylline clearance</strong>, necessitating a <strong>dose reduction to avoid</strong> <strong>toxic levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><u>Educational Objective:</u></span></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic smokers </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">may require</span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> increased doses of theophylline </span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">due to enhanced </span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">metabolism by induced liver enzymes</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dose Adjustments of Theophylline</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/09/picture8.jpg\" style=\"height:337px; width:1000px\" /></p>",
    "correct_choice_id": 43432,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8274,
    "choices": [
      {
        "id": 33063,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">RANK ligand inhibitor</span></span></span></p>"
      },
      {
        "id": 33064,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NMDA antagonist</span></span></span></p>"
      },
      {
        "id": 33065,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NK 1 receptor antagonist</span></span></span></p>"
      },
      {
        "id": 33066,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">5 HT3 antagonist</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mechanism of action of an aprepitant is?</span></span></span></p>",
    "unique_key": "Q1742514",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458009,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) NK 1 receptor antagonist</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Aprepitant</strong> functions as a<strong> neurokinin-1 (NK1) receptor antagonist</strong>. It is primarily used as an<strong> antiemetic </strong>to<strong> prevent delayed</strong> <strong>chemotherapy-induced nausea and vomiting (CINV)</strong>. The drug works by<strong> blocking the binding of substance P</strong>&mdash;a <strong>neuropeptide</strong> presents in<strong> both the central and peripheral nervous systems</strong>&mdash;to the <strong>NK1 receptors. Substance P</strong> is significantly involved in the <strong>initiation of nausea and vomiting.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. RANK ligand inhibitor:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect</strong> because <strong>RANK ligand inhibitors </strong>like <strong>denosumab </strong>are used to <strong>treat osteoporosis</strong> and <strong>bone</strong> <strong>metastases</strong>, not nausea and vomiting. These drugs<strong> inhibit RANK ligand,</strong> a protein essential for the<strong> formation and survival of</strong> <strong>osteoclasts,</strong> which are involved in<strong> bone resorption.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. NMDA antagonist:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect</strong> as <strong>NMDA antagonists,</strong> such as<strong> memantine</strong>, <strong>target cognitive </strong>decline in <strong>Alzheimer&rsquo;s disease</strong> rather than <strong>nausea and vomiting.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. 5 HT3 antagonist:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> because<strong> 5-HT3 antagonists, </strong>like<strong> ondansetron and granisetron</strong>, also<strong> prevent nausea and</strong> <strong>vomiting </strong>in settings like<strong> chemotherapy and post-operation </strong>but function by<strong> blocking 5-HT3 receptors</strong> on the <strong>vagus nerve</strong> and in the <strong>central nervous system</strong>, <strong>not<strong> </strong>NK1 receptors.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>NK1 receptor antagonist </strong>used primarily to <strong>prevent delayed chemotherapy-induced nausea and vomiting</strong> by<strong> inhibiting </strong>the action of <strong>substance P on NK1 receptors.</strong></span></span></span></p>",
    "correct_choice_id": 33065,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8276,
    "choices": [
      {
        "id": 33071,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">They are pro-drugs and undergo activation gradually</span></span></span></p>"
      },
      {
        "id": 33072,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">From stomach, these quickly reach the parietal cells and enter acid secretory canaliculi and stay there, blocking the secretion of acid for a long time</span></span></span></p>"
      },
      {
        "id": 33073,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">They irreversible inhibit the proton pump molecule </span></span></span></p>"
      },
      {
        "id": 33074,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">They are available as enteric coated capsules, from which drug is gradually released</span></span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Despite their short half-lives (2 hrs), proton pump inhibitors (PPIs) cause a prolonged suppression of acid secretion (up to 48 hrs) because?</span></span></p>",
    "unique_key": "Q6684452",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458010,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) They irreversible inhibit the proton pump molecule</span></span></span></strong></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Proton pump inhibitors (PPIs)</strong> work by binding <strong>irreversibly to the sulfhydryl groups of cysteines </strong>on the<strong> gastric H+, K+ -ATPase </strong>(the proton pump). This <strong>covalent binding</strong> results in the <strong>permanent inactivation of the pump molecules</strong> present at the time of drug administration. <strong>Acid secretion</strong> can only <strong>resume</strong> after <strong>new proton pump molecules</strong> are <strong>synthesized and transported to the luminal</strong> <strong>membrane</strong> of the stomach&rsquo;s <strong>parietal cells.</strong> This mechanism leads to a<strong> prolonged suppression of gastric acid secretion</strong>, lasting<strong> 24 to</strong> <strong>48 hours, </strong>despite the <strong>PPIs&rsquo; short plasma half-lives of 0.5 to 2 hours.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. They are pro-drugs and undergo activation gradually:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect </strong>because while<strong> PPIs</strong> are indeed <strong>prodrugs </strong>that are activated <strong>within</strong> the acidic environment of the <strong>parietal cells</strong>, the<strong> gradual activation does not </strong>directly contribute to the <strong>prolonged acid</strong> <strong>suppression</strong>. The prolongation comes from the <strong>irreversible inhibition of the pumps.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. From stomach, these quickly reach the parietal cells and enter acid secretory canaliculi and stay there, blocking the secretion of acid for a long time:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>because<strong> PPIs do not </strong>travel directly from the<strong> stomach to the parietal cells.</strong> They must first be <strong>absorbed from the intestine</strong> and then <strong>distributed to the parietal cells</strong> via the<strong> bloodstream.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. They are available as enteric coated capsules, from which drug is gradually released:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect </strong>as the<strong> enteric coating </strong>only serves to <strong>protect the drug </strong>from<strong> gastric acid degradation</strong> rather than <strong>prolonging its action </strong>at the <strong>site of the proton pumps.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Proton pump inhibitor</strong>s cause <strong>prolonged acid suppression</strong> by<strong> irreversibly binding to</strong> and <strong>inactivating the proton pumps</strong> in the stomach, and <strong>acid secretion </strong>only <strong>resumes </strong>once <strong>new pumps are synthesized and active.</strong></span></span></span></p>",
    "correct_choice_id": 33073,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8277,
    "choices": [
      {
        "id": 33075,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ranitidine combines with sucralfate and prevents its action</span></span></span></p>"
      },
      {
        "id": 33076,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Combination of these two drugs produces serious side effects like agranulocytosis</span></span></span></p>"
      },
      {
        "id": 33077,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ranitidine increases the gastric pH so sucralfate is not able to act</span></span></span></p>"
      },
      {
        "id": 33078,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sucralfate inhibits the absorption of ranitidine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient of peptic ulcer was prescribed ranitidine and sucralfate in the morning hours. Why is this combination incorrect?</span></span></p>",
    "unique_key": "Q6825346",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458011,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Ranitidine increases the gastric pH so sucralfate is not able to act</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Sucralfate </strong>is a medication <strong>used to treat</strong> ulcers by forming a<strong> protective barrier over the ulcer site.</strong> It requires an <strong>acidic environment</strong> <strong>(pH &lt; 4)</strong> to <strong>polymerize and function effectively.</strong> <strong>Ranitidine</strong>, an <strong>H2 receptor antagonist,</strong> works by <strong>reducing gastric acid secretion,</strong> thereby <strong>increasing gastric pH</strong>. When these<strong> two drugs</strong> are <strong>administered together,</strong> the<strong> increased pH</strong> caused by <strong>ranitidine </strong>can<strong> prevent</strong> <strong>sucralfate</strong> from <strong>polymerizing and forming </strong>its <strong>protective barrier, rendering it ineffective.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ranitidine combines with sucralfate and prevents its action:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>because <strong>ranitidine does not </strong>chemically combine with <strong>sucralfate</strong>; the issue is the<strong> pH environment alteration.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Combination of these two drugs produces serious side effects like agranulocytosis:</span></strong><span style=\"font-size:12.0pt\"> Incorrect as there is <strong>no</strong> evidence to suggest that <strong>agranulocytosis</strong> is a<strong> common side effect </strong>of combining these<strong> two drugs.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Sucralfate inhibits the absorption of ranitidine:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>because <strong>sucralfate does not</strong> affect the<strong> absorption of ranitidine;</strong> its primary interaction is with the<strong> gastric pH </strong>affecting its<strong> own mechanism of action.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Sucralfate</strong> needs an <strong>acidic environment</strong> to be<strong> effective.</strong> <strong>Co-administration </strong>with <strong>ranitidine,</strong> which <strong>raises gastric pH,</strong> can <strong>impair </strong>the <strong>effectiveness of sucralfate</strong> in treating <strong>ulcers.</strong></span></span></span></p>",
    "correct_choice_id": 33077,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8279,
    "choices": [
      {
        "id": 33083,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Community acquired pneumonia</span></span></span></p>"
      },
      {
        "id": 33084,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Clostridium difficile infection</span></span></span></p>"
      },
      {
        "id": 33085,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Osteoporosis</span></span></span></p>"
      },
      {
        "id": 33086,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypothyroidism</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the following adverse effects are associated with the use of proton pump inhibitors except?</span></span></p>",
    "unique_key": "Q3937347",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458012,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Hypothyroidism</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Proton pump inhibitors (PPIs) </strong>are commonly associated with <strong>several adverse effects</strong> due to their <strong>mechanism of reducing gastric acid secretion,</strong> but <strong>hypothyroidism </strong>is<strong> not</strong> one of them. The <strong>absence of </strong>any known link between <strong>PPI use </strong>and the development or exacerbation of <strong>thyroid function</strong> makes <strong>option D the correct answer </strong>as it is not an associated adverse effect.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Community acquired pneumonia:</span></strong><span style=\"font-size:12.0pt\"> Correctly associated with<strong> PPIs.</strong> Some studies have indicated an<strong> increased risk of</strong> <strong>pneumonia, </strong>particularly in vulnerable groups such as the<strong> elderly </strong>or those with <strong>existing respiratory conditions</strong>, possibly due to <strong>alterations in stomach pH </strong>affecting<strong> gut and respiratory flora.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Clostridium difficile infection:</span></strong><span style=\"font-size:12.0pt\"> <strong>Correctly </strong>associated with<strong> PPIs. </strong>The<strong> reduction in gastric acidity</strong> can lead to an environment <strong>more conducive</strong> to the <strong>growth of Clostridium difficile</strong>, potentially resulting in <strong>severe and life-threatening infections.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Osteoporosis:</span></strong><span style=\"font-size:12.0pt\"> <strong>Correctly </strong>associated with<strong> PPIs</strong>. <strong>Chronic</strong> use of <strong>PPIs</strong> may<strong> impact calcium absorption</strong> and <strong>bone metabolism,</strong> leading to an<strong> increased risk of osteoporosis </strong>and related<strong> fractures,</strong> especially in populations at <strong>risk like postmenopausal women</strong> and the<strong> elderly.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While <strong>PPIs are linked </strong>to several significant <strong>adverse effects</strong> such as <strong>increased risks of community-acquired pneumonia,</strong> <strong>Clostridium</strong> <strong>difficile infections</strong>, and<strong> osteoporosis</strong>, they are<strong> not </strong>associated with <strong>causing or worsening hypothyroidism.</strong></span></span></span></p>",
    "correct_choice_id": 33086,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  },
  {
    "id": 8284,
    "choices": [
      {
        "id": 33103,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Famotidine</span></span></p>"
      },
      {
        "id": 33104,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Omeprazole</span></span></p>"
      },
      {
        "id": 33105,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Misoprostol</span></span></p>"
      },
      {
        "id": 33106,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ranitidine</span></span></p>"
      }
    ],
    "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old pregnant woman has a history of rheumatoid arthritis which has been managed successfully with NSAIDs. However, she has recently visited her general practitioner complaining of burning epigastric pain worsened by food intake. Which of the following ulcer medication is most likely contraindicated in this patient?</span></span></p>",
    "unique_key": "Q7041910",
    "question_audio": null,
    "question_video": null,
    "map_id": 15458013,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Misoprostol </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Misoprostol,</strong> a<strong> prostaglandin E1 analog,</strong> is effective in preventing<strong> NSAID-induced ulcers</strong> due to <strong>its ability to increase gastric mucus</strong> and<strong> bicarbonate production</strong>, thus <strong>enhancing the stomach&#39;s protective lining</strong>. However,<strong> it is contraindicated during pregnancy </strong>as it <strong>stimulates uterine contractions</strong>, which can<strong> lead to miscarriage</strong>. Therefore, it is <strong>not suitable</strong> for use by <strong>pregnant women</strong>, making it the<strong> contraindicated medication</strong> in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Famotidine:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>as Famotidine, an <strong>H2 receptor antagonist,</strong> is generally <strong>considered safe</strong> for use <strong>during pregnancy</strong>. It works by <strong>reducing stomach acid</strong> and is <strong>not </strong>known to<strong> harm the fetus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Omeprazole:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect </strong>because <strong>Omeprazole</strong>, a<strong> proton pump inhibitor</strong>, is also <strong>used </strong>to manage ulcer symptoms by <strong>reducing</strong> <strong>acid production. </strong>While its <strong>use in pregnancy</strong> should be <strong>cautious, </strong>it is<strong> not</strong> specifically<strong> contraindicated </strong>like <strong>Misoprostol.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ranitidine:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect</strong> as Ranitidine, another<strong> H2 receptor antagonist,</strong> is typically <strong>safe</strong> for use <strong>during pregnancy. </strong>It works <strong>similarly to Famotidine</strong> by<strong> reducing gastric acid</strong> and is<strong> not </strong>associated with significant <strong>risks </strong>to the <strong>developing fetus.</strong></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Misoprostol</strong> is <strong>contraindicated in pregnant</strong> patients due to<strong> its potential </strong>to <strong>induce uterine contractions</strong> and <strong>risk</strong> causing <strong>abortion.</strong></span></span></span></p>",
    "correct_choice_id": 33105,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ],
    "explanation_video": null,
    "question_images": [],
    "explanation_images": []
  }
];
        let quizName = '00004 Mid Day Module (Pharma-4)';
        const quizFilename = '00004-mid-day-module-pharma-4-a0a39c58.html';
        let hierarchy = ["Cerebellum", "Mock Test", "Mid Day Module"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on navigation
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>